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Once optimistically believed to be a relic of the pre-antibiotic era, bacterial 
pathogens remain a substantial threat to human health, and the growing 
epidemic of antibiotic resistance has raised concerns for the long term prospects 
of antimicrobial therapy. By understanding the mechanisms used by bacteria to 
manipulate their host and cause disease, it is hypothesized that we might more 
rationally approach anti-infective therapeutic design.
Type III secretion systems (T3SS) are employed by some gram-negative 
human pathogens to manipulate the host environment. One T3SS subtype, 
known as the “injectisome,” delivers virulence factors directly into host cells. The 
other T3SS subtype secretes the the polymeric flagellar filament used for motility. 
While both systems share related elements of a cytoplasmic “sorting platform” 
that facilitates the hierarchical secretion of protein substrates, the structural 
mechanism of its assembly remains unclear.
The work described in this thesis makes strides towards the mechanistic 
understanding of T3SS sorting platform assembly by applying structural, 
biochemical, and genetic techniques to the characterization of the SctQ/FliM/FliN 
protein family and their interactions with other sorting platform components. 
These proteins uniquely possess Surface Presentation Of Antigens (SPOA) 
folds, and I will present the molecular structures of distinct homotypic and 
heterotypic SPOA-SPOA interactions in the Salmonella typhimurium SPI-1 
sorting platform protein SpaO (Chapter 2). In Chapter 3, I structurally 
characterize the interaction of the heterotypic SPOA complex with a regulator of 
the SPI-1 ATPase and demonstrate the necessity of the interaction for T3SS 
secretory function. Then, I will present the homologous structures from the S. 
typhimurium flagellar apparatus and compare and contrast them with their SPI-1 
homologues, providing an explanation for the observed subtype specificity in 
sorting platform assembly (Chapter 4). In Chapter 5, biochemical evidence for an 
interaction of the SpaO amino-terminal domain(s) with the homotypic SPOA 
complex is presented. These results provide a model for the subtype-specific 
assembly of T3SS sorting platforms and will support further mechanistic analysis 
and anti-virulence drug design (Chapter 6).
This document is dedicated to my family, without whose unconditional love and 
support this work would not have been possible.
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Portions of this chapter have been accepted for publication in the forthcoming 5th 
edition of “Virulence Mechanisms of Bacterial Pathogens” (ASM Press).
The clinical application of antibacterial small molecules (“antibiotics”) has 
revolutionized infectious disease medicine over the past six decades; however, 
the rise of antibiotic resistance has generated new challenges in the effective 
treatment of bacterial infections (1, 2). The United States Centers for Disease 
Control and Prevention estimates that 2 million Americans are infected by 
antibiotic resistant bacteria annually, resulting in more than 23,000 deaths (3). 
Hypothetically, therapeutic targeting of the machinery responsible for bacterial 
virulence in the human host might afford treatment strategies with a lower 
likelihood of evolution of resistance and decreased bystander damage to the host 
microflora (2, 4). To facilitate the discovery or design of such therapeutics, many 
have endeavored to understand the molecular basis for bacterial virulence, 
including the bacterial systems responsible for the delivery of toxic biomolecules 
from the bacterium to the host.
1.1 Type III secretion systems
Type III secretion systems (T3SS) afford gram-negative bacteria a most intimate 
means of altering the biology of their eukaryotic hosts — the direct delivery of 
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effector proteins from the bacterial cytoplasm to that of the eukaryote (5, 6). 
T3SS utilize a conserved set of homologous gene products to assemble the 
nanosyringe “injectisomes” capable of traversing the three lipid membranes, 
peptidoglycan layer and extracellular space that form a barrier to the direct 
delivery of proteins from bacterium to host. While the injectisome is 
architecturally similar across disparate gram-negatives, its applications are a 
study in diversity: T3SS are employed by both symbionts and pathogens; they 
target animals, plants, and protists; and they are used to manipulate a wide array 
of cellular activities and pathways.
T3SS have attracted intense scientific interest since the seminal work 
documenting their discovery was published over two decades ago (7-9). Given 
their role in the virulence of several human and plant pathogens (e.g. Salmonella 
enterica, Shigella flexneri, Yersinia spp., pathogenic Escherichia coli, Vibrio spp., 
Pseudomonas spp., Chlamydia spp.), T3SS are attractive targets for the 
discovery or design of novel anti-infective agents and vaccine approaches that 
disrupt toxin delivery. Conversely, harnessing T3SS function might also be of 
human benefit: as T3SS accomplish the biophysical feat of protein transduction 
across multiple membranes, their re-engineering for in vivo delivery of 
therapeutic proteins or in vitro production of protein reagents provides exciting 
prospects for future biomedical application. In either case, the manipulation of 
T3SS for human benefit will require highly refined mechanistic models of T3SS 
function. Drawing on research from multiple disciplines and employing 
complementary techniques, such models are beginning to emerge. In particular, 
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the application of structural biochemical approaches to the T3SS has provided 
numerous insights into the assembly and function of this system.
The focus of this chapter will be on T3SS function at the structural level; I 
will summarize the core findings that have shaped our understanding of the 
structure and function of these systems and highlight recent developments in the 
field. In turn, I will describe the T3SS secretory apparatus, consider its 
engagement with secretion substrates, and discuss the post-translational 
regulation of secretory function. Lastly, I will close with a discussion of the future 
prospects for the interrogation of structure-function relationships in the T3SS, 
and highlight those that will be the focus of the remaining chapters of this thesis.
1.2 Architecture of a nanosyringe
The genomic islands and virulence plasmids that support T3SS encode proteins 
of four broad classes: the components of the secretory system itself, the effector 
substrates, their chaperones, and transcriptional regulators. Working in concert, 
these components form a complete secretory system that de-chaperones and 
secretes substrates in a defined hierarchy and delivers them to the host 
cytoplasm. The repertoire of effector proteins secreted by a given T3SS is 
species-specific, as is the transcriptional network regulating T3SS expression 
(10). A discussion of these elements is beyond the scope of this document and 
has been expertly reviewed elsewhere (11-20). In contrast to the diverse, 
species-specific catalog of effector proteins and transcriptional regulators, the 
nanosyringe-like secretory machinery is well-conserved across species, and 
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advances in our mechanistic understanding of one species’ injectisome are often 
applicable to others. 
The core secretion machinery of the T3SS comprises a homologous set of 
approximately two-dozen gene products. Because of the high degree of 
homology of some components of the system, a universal nomenclature was 
previously suggested to facilitate cross-species comparisons (21), and recently 
others in the field have endorsed this naming system (22, 23). Similarly, I will 
employ this nomenclature (Table 1.1) wherever possible in this chapter. 
A subset of these proteins have conserved homologues in the flagellar 
apparatus (Table 1.1), which uses its own T3SS machine to assemble the 
flagellar filament (24). The flagellar apparatus employs a number of proteins for 
the flagellar-specific function of torque generation, and not surprisingly these 
components lack homologues in the injectisome. However, a set of inner 
membrane and cytoplasmic proteins thought to be involved in the targeting and 
secretion of substrates is conserved between the two systems. Given that these 
T3SS subtypes appear to have diverged from a common ancestor some 
hundreds of millions of years ago (25), their conservation is noteworthy. While the 
focus of this chapter and the majority of this thesis is the injectisome T3SS 
subtype, I will draw on the flagellar literature where it offers insights into 
injectisome function, and a subset of these flagellar homologues will be revisited 
in depth in Chapter 4.
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Table 1.1: A unified nomenclature for the homologous core components of 
the T3SS. Based on the nomenclature proposed by Hueck (21), with 













SctC InvG MxiD EscC YscC PscC
SctD PrgH MxiG EscD YscD PscD
SctJ PrgK MxiJ EscJ YscJ PscJ
Pilotin InvH MxiM YscW ExsB
Inner Rod SctI PrgJ MxiI EscI YscI PscI
Needle 
Fliament











SctV InvA MxiA EscV YscV 
(LcrD)
PcrD FlhA
SctR SpaP Spa24 EscR YscR PscR FliP
SctS SpaQ Spa9 EscS YscS PscS FliQ
SctT SpaR Spa29 EscT YscT PscT FliR




SipB IpaB EspD YopB PopB
SipC IpaC EspB YopD PopD
SipD IpaD EspA LcrV PcrV
ATPase SctN InvC Spa47 EscN YscN PscN FliI
Coiled Coil 
Linker






SctQ SpaO Spa33 SepQ YscQ PscQ FliM/FliN
SctK OrgA MxiK YscK
SctL OrgB MxiN EscL YscL PscL FliH
Export 
Regulator






The core conserved proteins of the T3SS form a double-membrane-spanning 
syringe-like structure (27, 28), including its extracellular needle-like appendage, 
and the associated cytoplasmic and membrane-integral secretion machinery 
(Figure 1.1). These components are collectively responsible for the delivery of 
effector proteins into the cytosol of the eukaryotic host cell (29, 30), and their 
structural and biochemical characterization has yielded significant insights into 
the processes of machine assembly and substrate secretion. 
The basal body. The bacterial double membrane and peptidoglycan layer are 
spanned by a stack of protein annuli known as the basal body (Figure 1.1). It 
comprises an outer membrane-anchored layer (SctC) and an inner membrane-
anchored layer (SctD and SctJ) that interface at a “neck” (31, 32). In electron 
microscopic (EM) reconstructions of the injectisome, SctC forms two distinct 
outer rings (OR1 and OR2), SctD and SctJ together form the distal inner ring 
(IR1), and the cytoplasmic amino terminus of SctD forms the innermost ring (IR2) 
(31). The highest resolution cryo-EM models of the Salmonella basal body reveal 
an overall three-fold rotational symmetry, with a resultant symmetry mismatch 
between the inner and outer layers: each basal body contains 24 SctD 
molecules, 24 SctJ molecules, and 15 SctC molecules (32). While the 24-fold 
symmetry of the inner membrane rings appears conserved across T3SS (33, 34), 
the stoichiometry of the the SctC outer membrane ring may vary between 
species (12-15 molecules per basal body), such that some systems have an 
overall 12-fold rotational symmetry (34, 35).
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Figure 1.1: Gross architecture of the T3SS. Cryo-EM reconstruction of the 
Salmonella typhimurium injectisome basal body at subnanometer resolution 
reveals its overall architecture. (A) Surface representation of  the highest 
resolution cryo-EM map (EMD 1875, contour level 0.0233) published by Marlovits 
and colleagues (32). Dashed lines indicate the positions of bacterial membranes 
in vivo. Abbreviations used: OR, outer ring; IR, inner ring; OM, outer membrane; 
IM, inner membrane. (B) An axial section through the map in (A). (C) Transverse 
sections through the map in (A) at the level of the neck (left) and IR1 (right).
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SctC is homologous to the Type II secretion system secretins (9, 36), and like 
other secretin family members requires a pilotin lipoprotein for its optimal 
localization and assembly (37-39). The membrane-embedded, β-rich region at 
the SctC carboxy terminus can be isolated and has been visualized by EM (35), 
but it has yet to be characterized at moderate or high-resolution. The periplasmic 
amino terminus of SctC contains a modular domain architecture (40) that 
interacts with the inner membrane ring (41, 42).
SctD and SctJ form the inner membrane rings (31). Each is anchored to 
the membrane by a single transmembrane helix, and SctJ is additionally lipidated 
near its amino terminus (43). Like the amino-terminal periplasmic region of SctC, 
the periplasmic domains of SctD and SctJ comprise a modular multidomain 
architecture (40). Despite differences in connectivity and little sequence 
homology, the mixed α/β domains of SctC, SctD, and SctJ show a similar three-
dimensional structure: two α-helices pack against the same face of a three strand 
β-sheet (40, 44). Superhelical crystal packing of the E. coil SctJ periplasmic 
region provided initial insights into the mechanism of inner membrane ring 
assembly (43), and the modular arrangement of these domains seems to 
promote oligomerization (45); however, none of these domains have been shown 
to clearly form annuli in solution, suggesting that additional constraints (e.g. 
protein-protein interactions or lipid membrane planarity) are critical for ring 
formation. Similarly, despite their 1:1 stoichiometry in the basal body, the 
periplasmic domains of SctD and SctJ have not been crystalized in complex.
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Might there be a specific functional advantage for the modular domain 
architecture common to the SctCDJ periplasmic regions? Recent in situ electron 
tomography of the Yersinia and Shigella injectisomes shows that the basal body 
has the ability to stretch in response to osmotic expansion of the periplasmic 
space (34). This resilience could be of potential importance for the maintenance 
of intact T3SS injectisomes under physiologic stresses and membrane 
deformations (34). Molecular dynamic simulations suggest that relative motions 
of the SctD periplasmic domains could account in part for this flexibility (34), but 
this hypothesis requires empiric support.
The amino-terminal cytoplasmic domain of SctD forms the innermost ring 
of the T3SS basal body. High-resolution structural analyses have determined this 
domain to have a forkhead-associated fold that interacts with cytoplasmic 
components of the T3SS (46-49). Forkhead-associated domains are β-
sandwiches that typically serve as phosphothreonine binding scaffolds, 
suggesting a means of signal-dependent recruitment of the cytoplasmic secretory 
apparatus to the basal body. However, the potential phosphopeptide binding 
residues are not conserved among T3SS (48), and the precise nature of the 
interactions between SctD and the cytoplasmic apparatus remains to be 
determined.
Within the central lumen of the basal body annuli, SctI is believed to form 
a cylindrical “inner rod” (31) structure that may support the extracellular needle 
filament. Computational methods have suggested a predominantly α-helical 
structure for SctI similar to that of the needle filament protomer (below); however, 
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structural analyses of Salmonella and Shigella SctI in solution showed little 
secondary or tertiary structure (50). It remains to be determined whether SctI can 
adopt a stable fold within the confines of the basal body. The functional 
significance of the inner rod in the regulation of needle length and secretion 
substrate switching will be discussed below. 
Direct structural characterization of the T3SS basal body epitomizes the 
challenges associated with the interrogation of high-molecular weight 
macromolecular machines: the assembly spans two membranes and a layer of 
peptidoglycan, and in situ electron tomographic analyses suggest that the basal 
body is capable of substantial conformational dynamism (34). As direct, high-
resolution structural characterization of the assembled T3SS basal body has not 
yet been possible, a multidisciplinary approach integrating cryo-EM maps, X-ray 
crystallographic domain structures, biochemical analyses and computer modeling 
has yielded a high-probability static model for injectisome architecture (51) 
(Figure 1.2). Such “hybrid” models will allow the testing of molecular-level 
hypotheses about ring assembly until the structure of the T3SS basal body has 
been determined at high-resolution in toto. 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Figure 1.2: Hybrid models of basal body structure. (A) Computational 
modeling of the neck (SctC, PDB 3J1V), IR1 (SctD, PDB 3J1X), and IR2 (SctD, 
PDB 3J1W) annuli of the Salmonella typhimurium basal body. No high resolution 
structural information is available for the basal body above the neck. (B) In this 
model, complementary electrostatic surfaces support ring building, as shown for 
the SctD periplasmic domains.  Note the modular domain architecture 
(enumerated 1, 2, 3) for SctDperiplasmic. 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The inner membrane machinery. Five highly conserved inner membrane proteins 
(SctRSTUV) are necessary for the function of the pathogenic T3SS; however 
their individual functions are unclear. It is worth noting these proteins show a high 
degree of sequence homology to components of the evolutionarily related 
flagellar T3SS (Table 1), and may represent a functional core, serving critical 
chemical roles in initiating or powering protein secretion. 
Among the SctRSTUV cohort, SctU and SctV possess cytoplasmic 
domains in addition to their transmembrane helices, and these domains have 
been best characterized to date. The cytoplasmic region of SctV contains a 
modular array of small domains (52-54) and crystallographic data suggest SctV 
may nonamerize (54). Intriguingly, such an oligomer is well suited to fit in a torus 
of SctV-associated density observed 5-10 nm beneath the basal body in EM 
reconstructions of the T3SS (34, 54). Lea and colleagues (54) have forwarded 
the hypothesis that this SctV homo-oligomer may serve as a “cage” to facilitate 
the complete unfolding of folded or partially unfolded secretion substrates, but 
this possibility has not yet been experimentally validated. The cytoplasmic region 
of SctU is considerably smaller than that of SctV and contains an autoprotease 
(55); its potential role in the regulation of secretion will be discussed below.
SctRSTUV are important in the organized, stepwise assembly of the T3SS 
basal body. Galán and colleagues (56) employed a combination of genetic and 
structural approaches to show that SctRSTUV help to organize the SctDJ inner 
membrane rings. Subsequently, the SctC ring and cytoplasmic machinery (below) 
are recruited, and the inner rod and needle polymers assembled (23). While 
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SctRSTUV are individually not strictly necessary for the formation of the SctCDJ 
basal body, the efficiency of basal body assembly is significantly decreased in 
their absence (56). 
The needle filament. A needle-like filament tens of nanometers in length 
protrudes from the extracellular face of the T3SS basal body (27, 57). The needle 
is formed by a helical assembly of the protein SctF, with an outer diameter of 8 
nm and an inner pore diameter of 2.5 nm (58). The apparent similarity of the 
T3SS basal body and needle filament to a macroscopic syringe makes it 
tempting to speculate that the T3SS directly injects its substrates into the host 
cell cytoplasm, with the needle filament serving as a conduit for the passage of 
partially unfolded effector proteins. Until recently, this hypothesis lacked direct 
empirical support, and alternative “non-injectisome” models for T3SS effector 
delivery had been proposed (59). Analyzing substrate-trapped injectisomes by 
cryo-EM, Marlovits and colleagues (60) and Kolbe and colleagues (61) 
demonstrated the presence of additional density in the lumen of the T3SS needle 
filament, consistent with the passage of partially unfolded substrate molecules 
through the needle.
High-resolution structures of monomeric SctF mutants (62) or chaperone-
bound SctF (63, 64), have allowed the characterization of the needle protomer 
fold.  SctF is a hairpin of alpha helices with an intervening conserved PXXP 
motif. The oligomeric nature of the needle filament had posed a practical barrier 
to high-resolution structure determination for the intact assembly. Recent hybrid 
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approaches combining cryo-EM with solid state nuclear magnetic resonance 
spectroscopy (NMR) and computational modeling have since afforded such a 
model for both the Salmonella (58) and Shigella (65) needle filaments. In these 
models, the SctF amino terminus is oriented towards the convex needle exterior, 
the carboxy terminus towards the lumen, and the apex loop connecting the two 
alpha helices points away from the bacterium. It should be noted that this 
arrangement is in contrast to prior lower resolution models (66), which oriented 
the SctF amino terminus towards the needle lumen. This correction is significant: 
the orientation of SctF protomers in the solid state NMR models is such that the 
lumen walls are formed by highly conserved residues, consistent with the 
passage of secretion substrates through the lumen (58, 65).
Assembly of needle filaments of a given length is necessary for the proper 
infectivity of T3SS-bearing pathogens, possibly matching the dimensions of host-
pathogen adhesion complexes (67). How, though, is the length of the needle 
filament controlled? SctP regulates the length of the needle filament in several 
species (68-70). In Yersinia spp., the number of residues in SctP correlates with 
needle filament length, leading to the hypothesis that SctP functions as a 
“molecular ruler” (70). That is, SctP might attach at one end to the basal body or 
cytoplasmic apparatus and at the other end to the growing needle filament, and 
once SctP was stretched beyond a given length, it would signal to the secretion 
apparatus to change substrates. 
In contrast to the molecular ruler model, work in Salmonella suggest that 
SctP regulates needle length through control of inner rod assembly (57). 
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Salmonella lacking SctP show decreased density in the inner rod-supporting 
socket region, lack a polymerized inner rod, and generate long needles (57, 71). 
Accordingly, Galán and colleagues hypothesized that completion of inner rod 
assembly terminates needle growth in a SctP-dependent fashion. Consistent with 
this “timer” model of length control (23), overexpression of SctF or SctI leads to 
longer or shorter needles, respectively (57). Moreover, alanine-scanning 
mutagenesis analyses of the inner rod protein SctI in Salmonella revealed 
numerous point mutations that increased needle length without compromising 
secretory function, perhaps by slowing the rate of inner rod polymerization (71). 
Intriguingly, the elongated needles generated by most of these mutants remained 
attached to the basal body (71), in contrast to those produced by sctP deletion 
mutants, which are easily sheared off (57). This observation is consistent with the 
hypothesis that the polymerized inner rod joins with the needle filament, 
anchoring it to the basal body (71).
The needle tip and translocon pore. At the tip of the T3SS needle filament is a 
pentameric cap formed by the hydrophilic translocator protein (72, 73). The 
needle tip is believed to interact directly with the host cell surface to facilitate the 
insertion of a multimeric pore (74, 75), thus completing the cytoplasm-to-
cytoplasm protein conduit. The structure and function of the needle tip is of 
particular biomedical interest, as the hydrophilic translocator protein is a 
protective antigen in anti-Yersinia vaccine formulations (76) and is a target of 
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recently developed passive immunization strategies for the treatment of 
Pseudomonas aeruginosa infections (77).
X-ray crystallographic analysis of the monomeric tip protein from several 
species reveals some conserved architectural features (78, 79): the tips of all 
species show an elongated coiled coil region and a central mixed α/β 
subdomain. The overall structure of the tip protein shows some interspecies 
variation though, with Salmonella/Shigella SipD/IpaD possessing an amino-
terminal autochaperoning subdomain (79) lacked by the Yersinia/Pseudomonas 
LcrV/PcrV tip proteins (23, 75). High-resolution models of the pentameric needle 
tip are not available, but low resolution negative stain EM models have offered 
some insight into the organization of the needle tip. While both appear 
pentameric, the Shigella tip complex is narrow and elongated relative to that of 
the Yersinia tip (72, 73), and fitting the Shigella IpaD monomeric crystal structure 
into the EM map required a significant rearrangement of the mixed α/β domain 
(73), suggesting substantial conformational changes upon incorporation into the 
tip complex. 
Attempts to model the tip protein-needle filament interaction at high-
resolution using NMR or X-ray crystallographic data have so far proven 
challenging, with incompatibilities arising between the proposed models and 
other data sets (80-82). The crystal structure of a Salmonella SctF-SipD fusion 
protein identified a potential binding mode for the tip with the needle (80); 
however, modeling the fusion structure onto the solid state NMR model of the 
needle filament (58) resulted in steric clashes, suggesting that artifactual 
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constraints imposed by the protein fusion strategy biased the architecture of the 
complex (82). Regardless, a synthesis of the available data shows that the 
needle filament interacts with the tip protein at least in part through its elongated 
coiled coil, a motif observed in all T3SS tip proteins described to date.
EM and biochemical analyses have shown that the Shigella tip complex is 
actually a heteropentamer containing four copies of the hydrophilic translocator 
IpaD and one copy of the hydrophobic translocator IpaB (81). A refined tip model 
incorporating this insight is similar to previous models, in that the amino and 
carboxy termini of IpaD are oriented towards the needle filament, with portions of 
the coiled coil region contacting the needle. However, the refined model presents 
an IpaD orientation consistent with antibody binding data and the 
heteropentameric architecture explains the transition from a helical needle 
filament to a nearly flat-topped tip complex (81).
In contrast to the annular, pentameric tip complexes observed for other 
T3SS, enteropathogenic E. coli possess a long filamentous needle accessory 
comprised of EspA, the SipD/IpaD/LcrV/PcrV homologue (83). EspA forms a 
helical filament similar to the SctF needle, with an internal diameter of 
approximately 2.5 nm (84), suggesting that it functions to extend the T3SS 
transport conduit. Filling a functional niche similar to needle filament length 
control in other T3SS, E. coli EspA polymers may adapt the injectisome to reach 
the target cell membrane beneath the intestinal glycocalyx (75).
The translocon permeating the host cell membrane is formed by the 
hydrophobic translocators SipB/SipC in Salmonella and their homologues (Table 
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1). Experiments in red blood cell membranes have shown that the needle tip is 
crucial for the insertion of the hydrophobic translocators into the host membrane 
and/or the organization of inserted translocators into functional pores (74, 85). 
While numerous experimental approaches have been employed to characterize 
the pore diameter and structure of the translocon (75), direct structural 
interrogation of native translocons is lacking. Intriguingly, the amino-termini of 
Salmonella SipB and Shigella IpaB contain extended coiled coils reminiscent of 
the colicin family of bacteriocins (86), which are known to function in the delivery 
of protein toxins across bacterial membranes. However, the precise mechanisms 
of host cell recognition, membrane insertion, pore formation, and protein 
translocation remain unclear for the T3SS translocon.
1.3 Substrate recruitment and secretion
T3SS secrete only a small fraction of the proteins present in the bacterial cytosol 
(87), and do so in a defined hierarchy. How does the T3SS select its substrates, 
how is their secretion hierarchy maintained, and what is the mechanism of 
secretion? A combination of genetic, biochemical, and structural data provide 
insight into the role of cytoplasmic injectisome-associated proteins in these 
processes.
Secretion chaperones. The amino-terminal ~100 amino acids of T3SS substrates 
possess two secretion signals: an unstructured extreme amino terminus followed 
by a chaperone-binding region. While the extreme amino-termini of T3SS 
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substrates are highly variable, computational approaches have identified 
commonalities in the chemical composition of this secretion signal (88-90): the 
first ~15 amino acids in an effector sequence are enriched in serine, threonine, 
isoleucine, and proline. Indeed, an effector with a synthetic, amphipathic poly-
serine/isoleucine secretion signal was secreted by Yersinia even in the absence 
of the second secretion signal (its secretion chaperone) (91). However, other 
studies have shown that chaperone-substrate interactions are necessary for 
targeting substrates specifically to the injectisome T3SS, as the extreme amino-
terminal secretion signal sequence can facilitate injectisome substrate export 
through the flagellar apparatus in the absence of a chaperone-binding domain 
(92). This finding suggests that the extreme amino-terminal secretion signal is 
evolutionarily “ancient” and shared by both types of T3SS (92).
Downstream of the amino-terminal secretion signal, each secretion 
substrate is recognized by a specific chaperone protein that maintains the bound 
region of the substrate in a partially unfolded state (93). It is hypothesized that 
this nonglobular conformation primes the substrate for secretion through the 
narrow aperture of the T3SS conduit (94). Chaperones can be classified by their 
structure and substrate type (26), as follows: Class IA chaperones are mixed α/β 
homodimers that bind to one effector; Class IB are structurally similar to IA but 
bind multiple effectors; Class II are alpha helical tetratricopeptide repeat (TPR) 
proteins that bind to translocon proteins; and Class III are heterodimeric TPR 
proteins that bind SctF needle filament protomers. It should be noted that while 
the premature polymerization of SipD/IpaD tip proteins is prevented by their 
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autochaperoning domain (79), tip proteins in Yersinia and Pseudomonas utilize a 
unique chaperone (LcrG/PcrG) to stabilize their tip protein monomers (95).
Like the extreme amino-terminal secretion signal, the chaperone-binding 
sequences of secretion substrates are variable. However, Class I chaperone 
recognition of a conserved β-strand(s) is a common feature of a diverse array of 
T3SS effectors (96), and it is conserved from animal to plant pathogens (97) 
(Figure 1.3). Indeed, the sparse sequence conservation associated with the “β-
motif” (96) can be used to recognize previously unknown T3SS effector proteins 
(98). In contrast, Class II and III TPR chaperones can recognize substrate 
sequences in either extended unstructured or α-helical conformations; the 
commonality here is that the TPR concavity is used to bind the substrate (26) 
(Figure 1.3).
The aforementioned substrate secretion signals are not only necessary for 
protein secretion through the T3SS, they are sufficient. Fusion of the secretion 
signal and chaperone-binding domain from endogenous T3SS substrates to 
heterologously expressed proteins results in their secretion through the T3SS 
(99), provided they can be properly unfolded for transit through the needle (60, 
61). While this observation is noteworthy for its mechanistic insight into the 
targeting of virulence factors for secretion, it has allowed the benevolent re-
engineering of the system to deliver protective antigens in vaccine design (100) 
and the large scale production of challenging protein reagents, like spider silk 
(101). 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Figure 1.3: Chaperone-substrate interactions. Structural distinctions between 
effector-chaperone and translocator-chaperone complexes. (A) The structure of 
the Salmonella effector SipA chaperone-binding domain (CBD, red and yellow) in 
complex with the Class IB chaperone InvB (2 protomers: dark gray and light 
gray). PDB 2FM8 (52). The structurally conserved β-motif is highlighted in yellow. 
(B) The SipA β-motif is bound by a hydrophobic (gray) patch on the InvB surface 
(blue/gray). (C) Superposition of the CBDs from effectors from multiple species 
shows a common binding mode marked by the structurally conserved β-motif. 
The prototypical Class I chaperone SicP is shown in place of the various 
chaperones. PDB codes: YopN, 1XKP (102); YopE, 1L2W (103); YscM2, 1TTW 
(104); SptP-SicP, 1JYO (93); SipA, 2FM8 (52); HopA1, 4G6T (97). (D) The 
Yersinia translocator YopD CBD (red) lacks secondary structure and is bound by 
the concave cleft of the Class II chaperone SycD (gray). PDB 4AM9 (105).
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The ATPase. Both the injectisome and flagellar T3SS include an ATPase with 
notable sequence homology to the β subunit of the F0F1 ATPase (106). For the 
injectisome, this ATPase is SctN; for the flagellar apparatus, FliI (Table 1.1). High-
resolution structural analysis of the E. coli SctN catalytic domain showed 
similarities to V- and F-type ATPases and confirmed that SctN hexamerization 
would be required for efficient ATP hydrolysis (107). Both FliI (108, 109) and SctN 
(106, 110) form such oligomers, but neither has been characterized structurally 
as a catalytically active hexamer. 
Interaction of chaperone-substrate complexes with the T3SS ATPase SctN 
causes the dechaperoning and unfolding of the substrate in an ATP hydrolysis-
dependent fashion (111). Given that disruption of tertiary structure is necessary to 
fit protein substrates in the 2.5 nm conduit of the needle filament (60, 61), it is not 
surprising that loss of function mutations in SctN cause the near complete 
abrogation of T3SS function (106, 111). Similarly, genomic deletion of fliI severely 
compromises flagellar filament assembly (112-115). Consistent with the role of 
SctN in preparing substrates for export, SctN/FliI-dependent density is observed 
directly beneath the T3SS basal body by EM (116, 117). The partial structural 
similarity of SctO/FliJ with the γ-subunit of F-type ATPases and the ability of FliJ 
to stimulate FliI hexamerization (109) has led to the hypothesis that this coiled 
coil containing protein (118) might connect oligomeric SctN to the SctV export 
gate, thus linking the sub-basal body toruses of electron density (54). However, 
the mere presence of a coiled coil is insufficient evidence to ascribe a γ-like 
function to SctO (23), and its precise role remains to be determined.
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Given the ATPase activity of SctN/FliI, it is tempting to speculate that ATP 
hydrolysis provides the free-energy for protein secretion; however, chemical and 
genetic analyses show that SctN/FliI is not the sole energizer of the T3SS. 
Experiments with the protonophore carbonyl cyanide m-chlorophenyl hydrazone 
have shown that the inner membrane proton motive force is necessary for 
secretion by both injectisome (119) and flagellar (112, 113) T3SS. Additionally, 
the flagellar assembly defect of ATPase deletion mutants can be at least partially 
corrected by mutations that alter the export apparatus, increase substrate levels, 
or increase the magnitude of the proton motive force (112-114). A similar result 
was recently reported for SPI-1 T3SS in Salmonella (114). These results suggest 
that under sufficiently permissive conditions, the actual transit of substrates into 
and/or through the conduit is powered by the proton motive force. However, one 
must interpret these results with some caution, as ionophores can significantly 
perturb cellular physiology (120) and SctN-independent injectisome secretion of 
a substrate requiring dechaperoning has not yet been demonstrated (114). A 
reasonable synthesis of the available data might surmise that both ATP 
hydrolysis and the proton motive force are important for energizing T3SS: the 
SctN/FliI ATPase functions to dechaperone and begin unfolding the secretion 
substrates with optimal efficiency under (non-ideal) physiologic conditions, while 
the proton motive force is responsible for the apical transit of the nonglobular 
substrate (114). 
Regardless of the quantitative contributions of either energy source, the 
mechanics of secretion remain poorly understood. There are no available high-
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resolution structural models of the interaction between chaperone-substrate 
complexes and the SctN ATPase. One computational model suggests a mode of 
ATPase-chaperone interaction based on structural similarities between Class I 
chaperones and the F-type ATPase γ-subunit (121). While this model and the 
accompanying biochemical data are consistent with the observation that 
relatively carboxy-terminal residues of SctN interact with chaperones (121), its 
structural accuracy lacks empiric support. Recent small angle X-ray scattering 
(SAXS) data suggest an alternative model for the interaction of substrates, 
chaperones, and the ATPase. Complexes of the Salmonella effector-chaperone 
pair SopB-SigE are able to hexamerize in a concentration dependent manner 
with dimensions comparable to the hexameric models of the ATPase (122). While 
it is too early to say whether other chaperone-effector complexes can oligomerize 
(123), whether these oligomers can interact with SctN, or whether such 
interactions — even if physically possible — are physiologically relevant, these 
results raise the possibility of alternate ATPase-cargo stoichiometries.
Recent solution NMR analyses suggest an interesting role for chaperone 
structure in the targeting of substrates to the T3SS. In solution, the E. coli 
chaperone CesAB is a partially folded molten globule (124) that does not interact 
with the hexameric SctN (125). However, upon binding to its substrate — the 
EspA tip filament protein — CesAB becomes fully structured and is able to bind 
SctN (125). The binding site for SctN was mapped onto the CesAB-EspA 
heterodimer, where it covered regions of CesAB unstructured in the absence of 
substrate (125). Consistent with the hypothesis that substrate-induced folding of 
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the chaperone allows for targeting to the ATPase, a mutation-stabilized, 
structured CesAB homodimer was able to bind SctN in the absence of substrate 
(125). While it remains to be determined whether similar disorder-to-order 
transitions effect SctN binding for other chaperone classes, these results are 
consistent with the role of chaperone-substrate interactions in targeting 
substrates for secretion. Additionally, the observation that substrate-chaperone 
complexes are recognized by hexameric SctN, but not its amino-terminally 
truncated monomeric form, suggests that ATPase hexamerization is critical for 
both hydrolytic catalysis and substrate recognition (125). 
The sorting platform. Located at the peripheral cytoplasmic face of the flagellar 
basal body is a ring of robust density in EM reconstructions (117). Known as the 
“C-ring,” this annulus is composed of the flagellar proteins FliM, FliN, and FliG, 
and it plays a role in flagellar motor function (torque generation) and rotational 
switching (24). FliM and FliN have an injectisome homologue with some 
conserved domains (SctQ), but torque generation by the injectisome is 
controversial (126) and a robust C-ring is absent in tomographic reconstructions 
of the injectisome basal body (34, 117). However, immuno-EM analysis of 
purified Shigella injectisomes shows localization of SctQ to the cytoplasmic face 
(127), suggesting that it plays some role in protein secretion or the regulation of 
the secretory process. Indeed, recent cryo-electron tomographic analyses of the 
Shigella injectisome have identified six SctQ-dependent “pods” of density 
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proximal to the cytoplasmic face of the basal body, forming a structure distinct 
from that of the flagellar C-ring (128).
Seminal biochemical and genetics work by Galán and colleagues revealed 
that SctQ forms a critical “sorting platform” for the T3SS (129). Affinity purification 
of SctQ from secretion-competent Salmonella produces high molecular weight 
complexes containing the SctN ATPase, regulatory proteins, chaperones and 
secretion substrates (129). Most notably, the sorting platform plays a role in the 
hierarchical secretion of substrates, queuing substrates in their appropriate order. 
For example, in Salmonella with assembled injectisomes, the sorting platform 
was predominantly occupied by translocon proteins, but genomic deletion of the 
translocators allowed the next tier of substrates (effector proteins) to access the 
sorting platform (129).
In addition to SctQ, formation of the sorting platform required the proteins 
SctK and SctL (129). While the role of SctK is at present unclear, biochemical 
analyses of the flagellar apparatus shed light on the potential function of SctL. 
SctL is a homologue of the flagellar protein FliH (Table 1.1). The SctL/FliH family 
is predicted to have a conserved domain architecture: an amino-terminal 
disordered region is followed by a coiled coil and then a mixed α/β domain (130). 
The carboxy terminus of FliH interacts with the amino-terminal oligomerization 
domain of FliI (130), inhibiting its ATPase activity (131). While sequence 
similarities between the FliH carboxy-terminal domain and the F-type ATPase δ-
subunit suggest a role for FliH as a “stator” (132), it is not obvious that FliH 
interacts with oligomeric FliI, and the structural details of this interaction are not 
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yet known. The amino terminus of FliH interacts with FliN (133), and this FliH-
FliN interaction is important (134) — if not absolutely necessary (135) — for the 
recruitment of FliI to the export apparatus. Given that the homologous 
injectisome complex (SctQ-SctL-SctN) forms a portion of the sorting platform and 
that chaperone-substrate complexes interact with the ATPase, these data 
suggest that one function of the SctQ sorting platform could be to localize 
chaperone-effector-ATPase complexes to the injectisome export apparatus. 
Indeed, Minamino, Namba and colleagues have hypothesized that the ATPase 
exists in two forms: an ATP-hydrolyzing hexamer and a dynamic substrate-
carrying monomer bound to FliH and the C-ring (136). Similarly, SctQ-injectisome 
interactions are dynamic in Yersinia, as injectisome-associated SctQ exchanges 
with a cytoplasmic pool with a half-time of approximately one minute (137).
Structural models of SctQ are a work in progress, and have focused to 
date on the carboxy-terminal third of the molecule. In Pseudomonas syringae, 
SctQ is spread over two open reading frames (hrcQA and hrcQB), much like FliM 
and FliN in the flagellar system. The structure of the carboxy-terminal domain of 
HrcQB is quite similar to that of the carboxy-terminal domain of FliN (138, 139); 
both domains are homodimers of the “Surface Presentation Of Antigens” (SPOA) 
fold, which appears to be unique to T3SS (Figure 1.4). The folded core of each 
protomer is an antiparallel β-sheet, and a loop from each protomer containing a 
β-strand and α-helix wraps around the β-sheet core of the other protomer. Like 
two left hands grasping one another, an antiparallel beta-sheet “palm” of each 
protomer is grasped by the “fingers” of the other, with a “thumb” protruding from 
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the top of the palm and strands from each protomer forming an anti-parallel beta 
sheet on the “floor” of the assembly.
 
Figure 1.4: The SPOA fold. (A) Ribbon model of the SPOA homodimer from 
Pseudomonas syringae HrcQB (PDB 1O9Y) (138). One protomer is colored as a 
rainbow from amino- (blue) to carboxy- (red) termini. Asterisk indicates the 
location of the β-sheet floor. In keeping with the “two left hands” architectural 
analogy, the “fingers,” “thumb,” and “palm” of one protomer are labeled. (B) 
Topology diagram of the HrcQB SPOA homodimer; generated using Pro-Origami 
(140). The rainbow pattern is not aligned between (A) and (B). 
 28
In Yersinia, SctQ is the product of a single open reading frame (as in most 
injectisomes), but the carboxy-terminal SPOA domain is duplicitously translated 
from an internal translation start site (141). Structurally, this homodimer is 
architecturally similar to its Pseudomonas and flagellar homologues. The 
homodimer produced by this translation product is able to interact with full-length 
SctQ and, at least in the Yersinia system, is necessary for secretion in vivo. In 
both the flagellar (142, 143) and injectisome (144) systems, this SPOA domain 
tetramerizes as a dimer of dimers, but appears to do so in different orientations in 
each system. Cross-linking analyses suggest that the FliN SPOA tetramers form 
a “doughnut” at the base of the C-ring (142), but high-resolution support for this 
arrangement is lacking. 
Despite the progress that has been made, numerous structural questions 
remain unanswered for the SctQ sorting platform. The function of the SPOA 
domain is unclear, SctQ-SctQ(SPOA) interactions have yet to be structurally 
characterized, and the structural basis for the interaction of SctL with SctQ has 
not yet been determined. Moreover, while the amino-terminal domains of FliM 
have well characterized functions in the regulation of flagellar rotation switching 
(145, 146), these motor functions are likely flagella-specific and involve 
interactions with partners not conserved from the flagellar apparatus to the 
injectisome (e.g. FliG and CheY). Thus, the function of the SctQ amino terminus 
is also unclear. Lastly, how and when SctQ or its soluble interaction partners 
interface with the basal body or export apparatus remains to be determined.
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Substrate switching. T3SS substrates are secreted in a defined order that is 
necessary for the proper assembly and function of the system (147, 148): 
secretion of the needle filament (SctF) and inner rod (SctI) is followed by 
secretion of the needle tip protein and translocon pore proteins, which is followed 
by the secretion of effector proteins. Thus, it seems that there are several 
sequential substrate “switching” events that must occur for the hierarchical 
secretion of substrates to be maintained (148). 
The first such switching event halts the extension of the growing needle 
filament and allows for secretion of the needle tip protein. As discussed above, 
the length of the needle filament is controlled by the assembly of the inner rod in 
a SctP-dependent fashion (57, 71). Full deletion of sctP locks the T3SS into a 
mode of exclusive SctF filament secretion; that is, deletion of sctP results in not 
only elongated needles, but a lack of translocon and effector secretion (68, 70, 
149, 150). Indeed, deletion of sctP results in the absence of translocon 
components from the SctQ sorting platform (129). However, small deletions in 
the amino-terminal regions of SctP alter needle length without compromising 
translocon secretion, suggesting that some portion of SctP performs a crucial 
switching function (150). Deletions within the conserved mixed α/β region at the 
carboxy terminus of the protein compromise translocon secretion (in addition to 
disrupting needle length regulation), and this presumptive domain has been 
termed the “type III secretion substrate specificity switch” (T3S4) domain (150). 
The three-dimensional structure of an injectisome T3S4 domain has not 
yet been determined, but the flagellar FliK T3S4 domain has been solved by 
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NMR (151).  The carboxy-terminal domain of FliK possesses two α-helices folded 
against a four-strand β-sheet (151), and the predicted structural conservation of 
these secondary structural elements in SctP suggests that this model may be 
generalizable to the injectisome. While it is still unclear at the molecular level how 
SctP functions to promote specificity switching, its interaction partners suggest 
some viable hypotheses. For example, the SctP T3S4 domain interacts with the 
SctO protein (152), suggesting that it may be able to transmit regulatory 
information to the SctN ATPase or the SctV export gate. Moreover, the T3S4 
domain interacts with the cytoplasmic autoprotease domain of SctU (153). Like 
SctP, SctU regulates the secretion of the the inner rod protein (154). The 
interaction between these two proteins is intriguing given that SctU interacts with 
components of the SctQ sorting platform and the SctV export apparatus (155), 
again suggesting mechanisms for the relay of switching information throughout 
the secretory apparatus.
The second major switching event distinguishes between translocon 
components and effector proteins (129). Deletion of translocon components 
allows for the localization of effector proteins to the sorting platform, consistent 
with a model where a gradient of substrate and/or chaperone affinities for the 
sorting platform controls the hierarchy of secretion (129). The identification of 
several classes of secretion apparatus mutants that can secrete effectors but not 
translocon proteins offers some insights into the establishment of secretion 
hierarchy. Deletion of sctW in Salmonella results in the specific loss of translocon 
component secretion (147). SctW binds the translocon proteins and their 
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chaperone in Salmonella (SicA) (147), and it is necessary for translocator binding 
to the SctQ sorting platform (129). These observations are consistent with SctW 
enhancing the affinity of translocon-containing complexes for the sorting platform. 
However, recent genetics data suggest the mechanism of hierarchy control for 
SctW may be more complex. A subset of the SctI alanine mutants identified by 
Lefebre and Galán (71) have normal needle lengths but phenocopy sctW 
deletion, and an interaction between SctW and SctI was recently reported in 
Shigella (156). Together, these data raise the possibility of SctW binding not only 
the sorting platform but also portions of the basal body.
Further clouding the role of SctW in T3SS is the observation of species-
specific effects of sctW mutation. In Yersinia and Shigella, SctW is secreted and 
sctW deletion does not specifically impair translocon protein secretion (157, 158). 
Moreover, the Yersinia SctW protein pair YopN/TyeA is part of a complex calcium 
response apparatus in the bacterial cytosol (159) that involves several Yersinia-
specific proteins (160, 161). While the structures of the Shigella and Yersinia 
SctW homologues have been determined (102, 162), a fuller understanding of 
SctW function (and its species-specific nuances) will require structural 
characterization in complex with other injectisome components.
In addition to its role in the first switching event, SctU is also involved in 
the second switch. The cytoplasmic domain of the SctU family autocatalyzes 
cleavage between the asparagine and proline residues of its conserved NPTH 
cleavage site (148). Alanine mutations on either side of the cleavage site cause 
aberrant specificity switching: translocon proteins are no longer secreted but 
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effector secretion remains intact (55, 157). An amphipathic linker connects the 
SctU transmembrane region to the cytoplasmic autoprotease, and this linker 
undergoes a disorder-to-order transition in the presence of anionic lipids (163). 
Introducing charge-altering mutations in the linker impaired T3SS function, 
suggesting that the ordering of the SctU linker against the bacterial inner 
membrane is crucial, perhaps favorably orienting the autoprotease domain for 
interactions with other members of the export apparatus (163). As mentioned 
above, SctU interacts with multiple members of the sorting platform, but the 
bases for these interactions — and the mechanisms by which they would effect 
specificity switching — are unclear.
Control of secretion. The T3SS can assemble a basal body, needle and tip, then 
pause in a “primed” state until the relevant stimulus arrives and secretion 
resumes. This strategy prevents the wanton waste of translocon and effector 
proteins. Interrogating this additional level of complexity is important to our full 
understanding of the pathobiology of T3SS, and may suggest routes to anti-
virulence compounds that prevent the activation of otherwise structurally 
competent injectisomes.
Bile salts play a regulatory role in the T3SS used by several enteric 
pathogens. The interaction of bile salts with the Shigella tip complex promotes 
IpaB recruitment to the tip, forming the heteropentameric tip complex described 
above (81, 164). In contrast, bile salts suppress Salmonella SPI-1 T3SS function 
(165). These observations provide an intriguing correlation between host 
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gastrointestinal physiology and pathogen virulence that ties environmental 
factors to the species-specific adaptation of the T3SS. Despite reports describing 
the interaction of bile salts with monomeric Shigella IpaD (166) and Salmonella 
SipD (80, 167), the structural basis for bile salt interaction with the intact tip 
complex has yet to be determined in either species, and so the mechanism of its 
regulatory activity remains unclear.
Contact with host cells stimulates the activation of T3SS in several species 
(168-170). In Salmonella, contact with target cells stimulates the secretion of the 
translocon proteins SipB and SipC (171), and in Shigella, interaction of the IpaD-
IpaB tip with liposomes resembling host cell membranes induces IpaC secretion 
(172). It is tempting to speculate that contact of the needle tip with the host cell 
sends a mechanical signal to the basal body and/or export apparatus that 
reinitiates secretion (10, 23, 173). As the connecting factor between the host cell 
surface and the basal body, the needle filament itself is a promising candidate for 
force transduction. Specific needle filament protein mutations can trap the 
Shigella T3SS in a constitutively active secretion mode, and one might 
hypothesize that these mutations stabilize needle filaments in a post-contact 
activated conformation (174). However, the filaments formed by these mutants 
do not exhibit the gross conformational changes one might expect if the needle 
filament architecture were transducing this signal (174). Alternatively, local 
changes in the tip environment may permit the secretion of substrates trapped 
within the needle by a closed tip, restarting secretion without requiring signal 
transduction to the bacterial cytoplasm or basal body (173). 
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Work from the Salmonella SPI-2 T3SS suggests a tantalizing third (and 
non-mutually exclusive) possibility, that the needle is not only a conduit for 
protein secretion, but a passageway for the diffusion of chemical signals (175). 
Salmonella makes use of two T3SS: broadly, the SPI-1 T3SS promotes cell 
invasion and subsequently the SPI-2 T3SS facilitates the formation of the 
Salmonella Containing Vacuole (SCV), an intracellular environment for 
Salmonella survival and replication (176). Holden and colleagues noted that 
priming of the SPI-2 T3SS requires exposure of the bacteria to low pH (as would 
be experienced in the endosomal compartment), but that triggering of effector 
secretion required a return to neutral pH (175). It is noteworthy that the SPI-2 
SctW protein was required for this transition (175), consistent with the apparent 
role of SctW in translocon-to-effector specificity switching in other systems 
(above). However, it is most intriguing that this switch required intact translocon 
components, suggesting that the neutral pH signal may be transduced from the 
host cell cytosol, through the translocon and needle, to the basal body and/or 
export apparatus (175). 
1.4 Summary
In the past 20 years, our models of T3SS structure and function have evolved 
substantially, from the first visualization of the injectisome architecture, to the 
high-resolution structural interrogation of many of its individual components. 
Combining these insights with a plethora of genetic and biochemical data, the 
molecular mechanics of this astounding secretory nanomachine are coming into 
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focus. However, numerous questions remain — the answers to which are critical 
to our understanding of bacterial virulence, the design of new therapeutics, and 
the imaginative re-engineering of the system. 
Despite the improvements in cryo-EM models of the injectisome, the 
precise architecture of the membrane embedded components of the T3SS is still 
unclear, as is the structural basis for their interactions with the soluble 
components of the system. The native structures of the filament-bound needle tip 
and the translocon in the host membrane must be determined to understand how 
the extracellular environment regulates secretion, how proteins penetrate to the 
host cytosol, and how to rationally design secretion-blocking vaccines. Although 
the constituents of the cytoplasmic sorting platform have been identified, the 
structural bases for their interactions are unknown: how the sorting platform 
assembles, how substrate-chaperone complexes engage the system, and how 
the numerous regulatory elements interact to govern a secretory hierarchy all 
remain to be determined.
Answering these questions is likely to require a hybrid approach, 
characterizing local interactions and large assemblies alike, and employing a 
range of structural and molecular techniques. However, it is clear that high-
resolution models of intact macromolecular assemblies (e.g. basal body, needle 
tip, translocon pore) would greatly advance the field. Much like the role that 
atomic models of the ribosome have played in the interrogation of its multiple 
functional states, one can imagine the watershed of insight that would come from 
successful visualization of the injectisome or sorting platform in each of their 
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several forms: needle-assembling, translocator-secreting, and effector-secreting. 
Ideally, these mechanistic insights will allow the uncoupling of some pathogenic 
gram-negative bacteria from virulence and/or the re-engineering of the 
nanosyringe for the benefit of biotechnology.
The work described in this thesis makes strides towards the mechanistic 
understanding of T3SS sorting platform assembly by applying structural, 
biochemical, and genetic techniques to the characterization of SctQ/FliM/FliN 
and their interactions with other sorting platform components.  I will present the 
molecular structures of distinct homotypic and heterotypic SPOA-SPOA 
interactions in the Salmonella typhimurium SPI-1 sorting platform protein SpaO 
(Chapter 2). In Chapter 3, I structurally characterize the interaction of the 
heterotypic SPOA complex with a regulator of the SPI-1 ATPase and 
demonstrate the necessity of the interaction for T3SS secretory function. Then, I 
will present the homologous structures from the S. typhimurium flagellar 
apparatus and compare and contrast them with their SPI-1 homologues, 
providing an explanation for the observed subtype specificity in sorting platform 
assembly (Chapter 4). In Chapter 5, biochemical evidence for an interaction of 
the SpaO amino-terminal domain(s) with the homotypic SPOA complex is 
presented. The implications of this work and potential future directions are 




SPOA-SPOA INTERACTIONS IN SpaO
Portions of Chapters 2-7 have been published previously (177): 
Notti et al. (2015). A common assembly module in injectisome and flagellar 
type III secretion sorting platforms. Nature Communications 6, 7125.
To date, the T3SS sorting platform has been most thoroughly characterized in S. 
typhimurium (129). This species contains three T3SS: two injectisomes (SPI-1 
and SPI-2, as discussed in Chapter 1) and a flagellar apparatus. As the genetic 
and biochemical characterization of the sorting platform explored the SPI-1 
constituents, I chose to begin my efforts there. For clarity and consistency with 
the primary literature, I will now refer to the relevant SPI-1 gene products by their 
Salmonella-specific names. 
2.1 Expression and purification of SpaO
The major constituent of the SPI-1 sorting platform is a 303-residue protein SpaO 
(SctQ) (129). SpaO was robustly heterologously expressed as a double 
hexahistidine fusion in E. coli and yielded soluble material by nickel-affiinity 
purification (Figure 2.1C). Like its Yersinia homologue, full length SpaO co-affinity 
purified with a small fragment (~14 kDa). In Yersinia, the ~11 kDa YscQ fragment 
is translated from an internal translation start site at M218 and is necessary for 
T3SS function (141). While SpaO lacks a potential initiator methionine codon in 
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this region of the gene, I hypothesized that a nearby valine GTG codon 
(ValGTG203, arrow in Figure 2.1A) with a putative upstream ribosomal binding site 
(Figure 2.1B) might be able to function as a cryptic translation start site. Indeed, 
mutation of the Val203 codon from GTG to GTT resulted in the loss of fragment 
expression and co-purification (Figure 2.1C). Intriguingly, in the absence of this 
carboxy-terminal fragment, the soluble yield of full length SpaO protein was 
greatly diminished, despite an identical amino acid sequence and overall similar 
expression levels (Figure 2.1C).  
The Yersinia YscQ carboxy-terminal fragment contains a SPOA domain as 
previously seen in Pseudomonas HrcQB and the flagellar protein FliN. 
Preliminary bioinformatic analyses — specifically, sequence homology and 
secondary structure prediction — suggested the presence of two putative SPOA 
domains in the carboxy-terminal half of SpaO, which we prospectively denote 
SPOA1 and SPOA2 (Figure 2.1A). The presumptive SPOA domain located within 
the cryptically translated carboxy-terminal fragment and at the carboxy terminus 
of the full length SpaO protein was 34% and 24% identical to its Y. 
pseudotuberculosis and P. syringae homologues, respectively, by Clustal Omega 
alignment (178). (These two structurally characterized SPOA domains are 26% 
identical to one another.) Putative SPOA1 showed lower sequence identity to the 
structurally characterized SPOAs from Yersinia and Pseudomonas (18% and 
19%, respectively), but showed 24% identity to S. typhimurium SPOA2 and 
secondary structure prediction was consistent with a SPOA fold. 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Figure 2.1: Bioinformatic analysis and heterologous expression of SpaO. 
(A) Secondary structure prediction and sequence homology suggest the 
presence of two putative SPOA domains in SpaO. Approximate domain 
boundaries are indicated beneath the block diagram. PSIPRED probability of 
helical character is plotted in red, strand in blue, and disorder in yellow. The 
arrow represents a predicted ValGTG203 internal translation start site. (B) SpaO 
genomic sequence and amino acid translation in the vicinity of codon 203. Select 
codon numbers appear at bottom. The putative cryptic translation initiation codon 
is highlighted in red. A purine rich region 8bp upstream of ValGTG203 is denoted 
as the hypothetical ribosomal binding site (RBS). (C) Heterologous expression of 
SpaO in E. coli. Coomassie-stained sodium dodecyl sulfate (SDS)- 
polyacrylamide gel electrophoresis (PAGE) gels showing the imidazole elution or 
whole cell lysates for recombinant expression experiments. The genotype of 
SpaO at codon 203 is shown over each lane and coexpression of the SPOA2 
containing construct SpaO(222-303) is indicated with a “+”. Presumptive 
chaperone contamination is indicated by a black asterisk. Red asterisks in the 
whole cell lysate gel indicate the bands corresponding to SpaO(203-303) and 
SpaO(222-303) (left and right, respectively).  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I hypothesized that the SPOA2 region of the cryptically expressed carboxy-
terminal SpaO fragment might mediate its interaction with the full length protein. 
Indeed, coexpression of double hexahistidine tagged SpaO(1-303, ValGTT203) 
with the SPOA2 construct SpaO(222-303) resulted in co-affinity purification of the 
two polypeptides over NiNTA resin (Figure 2.1C). Furthermore, coexpression of 
this SPOA2 containing fragment with the SpaO(1-303, ValGTT203) rescued the 
protein’s solubility defect, restoring it to wild-type levels (Figure 2.1C) and 
implicating the SPOA2 domain specifically in this phenotype.
Co-affinity purified complexes of full length SpaO with SPOA2-containing 
constructs remained partially intact over anion-exchange chromatography, with a 
fraction of SPOA2 separating from the full length protein (Figure 2.2A, compare i, 
ii, and iii). However, intact complexes remained associated over size exclusion 
chromatography (Figure 2.2B, see ii) and I endeavored to crystallize this complex 
for structure determination by X-ray diffraction.
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Figure 2.2: Purification of the SpaO-SPOA2 complex. (A) Full length SpaO 
and its co-purifying carboxy-terminal fragment were subjected to anion exchange 
chromatography (left). The blue trace shows UV absorbance at 280 nm (A280) 
and the brown trace shows conductance (G). At right, samples of the elution at 
three points (i, ii, and iii) are shown on a coomassie-stained SDS-PAGE gel. (B) 
Fractions of peaks “ii” and “iii” were further purified by size exclusion 
chromatography (left), and samples of the elution are shown at right processed 
and stained as in (A).
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2.2 Diffraction analysis of macromolecules: A brief overview
Before proceeding with further experimental description, it is prudent to briefly 
discuss the methodology of X-ray crystallography, as it will be central to much of 
the work presented here. (For a full resource, see Drenth and Mesters, ref. 180.) 
Over the past century, X-ray crystallography has revolutionized our 
understanding of small molecule and macromolecular structure by allowing the 
determination of the positions of individual atoms within a macromolecule (179). 
While it is now complemented by NMR spectroscopy and cryo-EM, X-ray 
crystallography was the first technique to allow the visualization of 
macromolecular structure at high (atomic or near-atomic) resolution. 
In order to determine the structure of a protein or protein complex by X-ray 
diffraction, the target must be packed into an ordered, three dimensional crystal 
lattice by exposure to an empirically determined solution of precipitants, buffers, 
salts, and additives. Exposure of the crystal to bright, collimated beams of X-ray 
photons results in interactions of the protein’s electrons with the incoming 
photons, changing their direction as they pass through the crystal. As a product 
of the repeating nature of the crystal lattice, patterned constructive and 
destructive interference of the scattered X-ray waves generates a stereotyped 
three dimensional array of spots measurable by X-ray detection equipment (a 
“diffraction pattern,” Figure 2.3). Individual spots are identified by integer indices 
h, k, and l, and their intensities can be measured with high accuracy. 
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Figure 2.3: X-ray diffraction analysis of macromolecules. Exposure of 
crystalline macromolecules generates a diffraction pattern of “reflections.” The 
intensity of these spots can be used to provide structural information about the 
macromolecule crystallized.
From these intensities, one can calculate a map of the electron density within the 
crystal lattice and build a molecular model of the crystallized protein’s structure 
(180). The electron density (𝛒) at a given point (x,y,z) within the crystal’s 
repeating unit cell is related to the diffraction pattern by Fourier transformation:
 
where V is the volume of the crystalline unit cell, F(h,k,l) is derived from the 
measured X-ray intensity at a given index (h,k,l), and α(h,k,l) is the phase angle 
of the wave at that index. While the X-ray intensities can be measured directly, 
the phase angles are not measured by the detector. This missing information 
creates the “phase problem” of X-ray crystallography: without the phase data, the 
electron density map cannot be determined from the X-ray diffraction pattern.






∑ F(h,k,l) e−2πi(hx+ky+lz)+iα (h,k,l )
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Phase information can be calculated by several methods, allowing for the 
successful determination of molecular structure from diffracted X-ray intensities. 
In this work, novel structures were solved by selenomethionine (SeMet) single 
wavelength anomalous diffraction (SAD). Many proteins produced in E. coli are 
compatible with the biosynthetic replacement of methionine sulfur atoms with 
selenium. Protein crystals derived from this selenium-doped material generate X-
ray diffraction patterns with selenium position-dependent asymmetries 
(“anomalous” diffraction). Whereas the intensities I(h,k,l) and I(-h,-k,-l) are 
normally equivalent, this is no longer the case in the presence of a structured 
anomalous scatterer, and these measurable intensity differences can be used to 
determine Se positions and starting estimates of phase angles. For derivative 
structures in this work, known partial structures were used to determine starting 
phase estimates; this method is known as molecular replacement.  In both cases, 
an iterative approach is used refine the molecular model and inferred phase 
angles against the empirical diffraction data until the fit between them has been 
optimized.
2.3 Structure of the SpaO SPOA2 homodimer
Full length SpaO in complex with separately translated SPOA2 was subjected to 
standard sparse matrix crystallization screening to generate crystals for 
diffraction analysis. While several conditions grew tetragonal crystals, these 
crystals were composed solely of the SPOA2 polypeptide and diffracted poorly. 
No crystals containing the full length SpaO protein were identified.
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In order to facilitate structural characterization of SpaO, I attempted to 
break SpaO into smaller domain constructs that might be more amenable to 
crystallization. Ideally, structural characterization of small modules within the full 
length protein might shed light on higher order structures or functions. Given the 
inherent crystallizability of SPOA2, I decided to begin with this domain.
Using the aforementioned bioinformatic information and preliminary 
diffraction data from SpaO(222-303), the SPOA2 containing construct was 
truncated to SpaO(232-297). This construct was solubly expressed in E. coli, and 
purified by Ni-affinity, anion exchange, and size exclusion chromatography 
(Figure 2.4). Ghosh and colleagues previously used multiangle light scattering to 
determine that the Y. pseudotuberculosis YscQ carboxy-terminal fragment exists 
as a dimer in solution (141). Similarly, I subjected SpaO(232-297) to dynamic 
light scattering (DLS) and found its hydrodynamic radius (20  Å ± 1  Å) and 
resulting estimated mass (16 kDa ± 1 kDa) to be consistent with a dimer 
(expected mass: 16 kDa) over a range of concentrations (Figure 2.4).
Crystals of SpaO(232-297) were obtained that routinely diffracted to high 
resolution (all crystallization and cryoprotection conditions are available in 
Chapter 7). SeMet incorporated SpaO(232-297) crystallized under the same 
conditions as native material and diffraction data were collected to 1.35 Å 
resolution (Figure 2.5 and Table 2.1). Given the high resolution data obtained 
from SeMet crystals, the model was refined against the SeMet data set. 
 46
Figure 2.4: Purification and solution behavior of SpaO(232-297). (A) Anion 
exchange chromatographic purification of SpaO(232-297). The blue trace shows 
UV absorbance at 280 nm and the brown trace shows conductance. Inset shows 
coomassie-stained gel of the Ni-NTA resin imidazole elution (E) and the main 
SourceQ elution peak (i). Note that the affinity tag was removed with human 
rhinovirus 3C protease prior to anion exchange chromatography. (B) Size 
exclusion chromatography purification of SpaO(232-297) subsequent to anion 
exchange chromatography. Inset shows coomassie-stained gel of the main peak 
(ii). (C) DLS data for SpaO(232-297). The data for 1mM protein is shown in the 
autocorrelation and regularization graphs. In the autocorrelation graph, the raw 
data is shown in blue and the regularization fit is shown in violet. Inset shows the 
estimated particle mass over a range of concentrations.
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Figure 2.5: Diffraction analysis of SpaO(232-297). (A) Representative 
diffraction image  for SpaO(232-297, SeMet). Image is truncated for fit. Edge 
resolution is 1.25 Å. Inset shows an example of the crystal form. (B) Zoomed 
view of the diffraction image in (A) highlighting high resolution spots. Resolution 
values shown correspond to spots immediately to their left. (C) Stereoimage of a 
selected region of the 2Fo-Fc electron density map for the 1.35 Å resolution 
SpaO(232-297) structure. The map is contoured to 1σ.
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The structure of SpaO(232-297) confirms the fold of the presumptive SPOA2 
domain as a bona fide SPOA fold (Figure 2.6). The construct forms a dimer in the 
crystallographic asymmetric unit, in which each protomer interfaces with the 
other in a “fingers-to-palm” arrangement, as described for the other structurally 
characterized SPOA homodimers (Figure 1.4). The SPOA2-SPOA2 interface 
buries 1898 Å2 from each protomer.
The conserved arrangement of β-strands is striking when comparing the 
topology diagrams of SpaO SPOA2 (Figure 2.6) with its P. syringae homologue 
(Figure 1.4). Indeed, the SpaO SPOA2 homodimer superposes on its Yersinia 
and Pseudomonas homologues with 2.24 Å and 3.05 Å r.m.s.d., respectively. The 
structural similarity is readily apparent, especially when viewing the structures 
from the “top” (Figure 2.7A, right). Comparison of the SpaO SPOA2 sequence 
with that of S. flexneri Spa33, Yersinia enterocolica YscQ, and P. aeruginosa 
PscQ (Figure 2.7E) reveals that the greatest sequence homology maps to the 
hydrophobic core and dimerization interface of the structure, as opposed to 
solvent exposed surfaces (Figure 2.7B,C). Thus it seems that dimer formation is 
likely to be a conserved structural feature of the SPOA2 domain, consistent with 
all described crystal structures. The dimer architecture creates clefts on the “top” 
and “bottom” of the assembly, and it is noteworthy that these crevices are 
somewhat structurally conserved, displaying electronegative surfaces in S. 
typhimurium and its homologues (Figure 2.7D, Y. pseudotuberculosis shown), 
despite inconsistent sequence homology.
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Figure 2.6: Structure of the SpaO SPOA2 homodimer. (A) Ribbon diagram of 
the SpaO(232-297) crystal structure. One protomer is shown in gray and the 
other in green. The structure is annotated as SPOA diagrams previously shown; 
asterisk indicates the β-sheet “floor.” (B) Topology diagram for the structure in (A) 
generated using Pro-Origami.
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Figure 2.7: Comparison of SpaO SPOA2 with known homologues. (A) The 
S. typhimurium, Y. pseudotuberculosis, and P. syringae SPOA2 homodimers are 
shown as backbone worm diagrams, superposed, and colored as indicated. (B) 
100% conserved (red) or highly conserved (orange) residues in the hydrophobic 
core of the SPOA2 homodimer. A shell of highly conserved residues surrounds 
F236. (C) Comparison of the degree of sequence conservation on the solvent 
exposed (bottom) and dimerization interface (top) surfaces of a protomer in the 
SPOA2 homodimer. Colored as in (B). (D) Electrostatic surface diagrams for the 
S. typhimurium, and Y. pseudotuberculosis SPOA2 homodimers highlighting 
structurally conserved electronegative clefts on the “top” and “bottom” of the 
dimer (dashed circles). (E) Excerpt of the M-COFFEE alignment of SpaO, S. 
flexneri Spa33, Y. enterocolica YscQ, and P. aeruginosa PscQ is shown 
beginning with SpaO V232. Asterisk denotes identity; colon, high conservation; 
period, low conservation.  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Figure 2.7: Comparison of SpaO SPOA2 with known homologues. 
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2.4 Structural basis for SpaO SPOA1-SPOA2 interactions
Constructs containing only the presumptive SPOA1 domain were insoluble and 
could not be refolded after affinity purification under denaturing conditions (Figure 
2.8A,B). However, constructs containing both presumptive SPOA1 and SPOA2 
(residues 140-297) were stable and soluble (Figure 2.8A). As this construct 
contains the ValGTT203 mutation, no free SPOA2 is translated. Ni-affinity purified 
SpaO(140-297) could be purified by subsequent anion exchange and size 
exclusion chromatography (Figure 2.9); however, this construct did not yield 
crystals when subjected to sparse matrix crystallization screening.
Figure 2.8: The putative SPOA1 of SpaO is stabilized by SPOA2. (A) 
Heterologous expression of double hexahistidine-tagged SpaO SPOA1 
(145-213) and SPOA1-SPOA2 (140-297) constructs in E. coli. A coomassie-
stained gel of the whole cell lysate (WCL) and soluble NiNTA imidazole elution 
(E) are shown for each construct. Red asterisks denote expression of the 
intended constructs as visualized in the WCL. (B) Attempted refolding of 
SpaO(145-213). NiNTA elution under denaturing conditions (Urea E) and the 
supernatant after refolding by dialysis and filtration of the insoluble material (RF 
Super.).
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Figure 2.9: Expression and purification of SpaO(140-297). Anion exchange 
(SourceQ, left) and size exclusion (Superdex75, right) chromatographic 
purification of SpaO(140-297). The blue trace shows UV absorbance at 280 nm 
and the brown trace shows conductance. Inset shows coomassie-stained gel of 
the Ni-NTA resin imidazole elution (E) and the main anion exchange and size 
exclusion chromatography elution peaks (i and ii, respectively). Note that the 
affinity tag was removed with human rhinovirus 3C protease prior to anion 
exchange chromatography (compare E and i).
To further characterize SpaO(140-297) in solution and refine expression 
constructs for crystallography, I analyzed its backbone amide resonances by 
solution NMR. Heteronuclear NMR experiments allow the identification of 
resonances corresponding to individual backbone amide protons in a protein, all 
of which can be simultaneously visualized in heteronuclear single quantum 
coherence spectroscopy (HSQC) or transverse relaxation-optimized 
spectroscopy (TROSY) spectra. As these resonances are very sensitive to the 
immediate chemical environment of a given amide proton, a fully assigned HSQC 
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or TROSY serves as the chemical “fingerprint” of a protein and offers insight into 
local secondary structure and likelihood of disorder for a given residue (181).
SpaO(140-297) was analyzed by solution NMR and using a standard suite 
of backbone assignment experiments, and 150 backbone amide proton 
resonances were assigned out of a possible 155 (Figure 2.10). An example set of 
linked, assigned amide resonances from one experiment in this suite (TROSY-
HNCA) is shown in Figure 2.10B.   The overall impression from the 15N-TROSY is 
one of a well dispersed pattern of amide resonances, consistent with a 
structured, folded globular protein. A set of resonances with sharp peaks and 
long relaxation times clustered around δ1H=8.25 is consistent with a region or 
regions of disorder (e.g. flexible linker, extended surface loops, or disordered 
termini). Chemical shift deviation analysis of backbone amide resonances 
suggested a secondary structure pattern similar to that predicted by bioinformatic 
analyses: two SPOA domains connected by a flexible linker (Figure 2.11).
Figure 2.10: NMR analysis of SpaO(140-297). (A) 15N-TROSY for 
SpaO(140-297) annotated with backbone amide resonance assignments in red. 
(B) Annotated strip-view of a portion of the TROSY-HNCA experiment used as 
part of a suite of backbone assignment experiments. Linked resonances are 
indicated with red asterisks connected with dotted lines.  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The putative SPOA1 domain might be solubilized by the presence of SPOA2 
(see Figure 2.8) in one of two ways: the two regions might interact directly, 
burying otherwise aggregation prone surfaces, or the two regions might not 
interact directly, and the presence of SPOA2 solubilizes SPOA1 simply by virtue 
of its own high solubility. I hypothesized the former to be the case — that SPOA2 
directly interacts with and solublizes SPOA1, perhaps in a manner structurally 
analogous to SPOA2 homodimer formation. Consistent with this hypothesis, the 
SPOA1-containing construct SpaO(145-213) could be co-refolded with SPOA2 
(SpaO(232-297), Figure 2.12). Anion-exchange chromatography allowed the 
separation of the SPOA1-SPOA2 complex (Figure 2.12, peak “i”) from excess 
free dimeric SPOA2 (Figure 2.12, peak “ii”), and the complex remained stable 
over size exclusion chromatography, despite lacking the polypeptide linker that 
normally connects the two regions covalently. 
One might hypothesize that the disordered region between the SPOA 
domains (predicted by bioinformatics and supported by NMR chemical shift 
analysis) might have previously been hindering crystallization, by virtue of its high 
conformational entropy. Thus, I hypothesized that this linker-free SPOA1-SPOA2 
complex might be more amenable to crystallization than SpaO(140-297). Indeed, 
the SpaO(145-213) + SpaO(232-297) complex crystalized, and its structure was 
determined to 2.9 Å resolution (Figure 2.13, Table 2.2). Compared to the SPOA2 
homodimer crystals that diffracted to high resolution, the more weakly diffracting 
SPOA1-SPOA2 crystals had a much higher solvent content (44% and 62%).
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Figure 2.12: Purification of SpaO(145-213) + SpaO(232-297). Anion exchange 
(SourceQ, left) chromatographic purification of co-refolded SpaO(145-213) + 
SpaO(232-297). The blue trace shows UV absorbance at 280 nm and the brown 
trace shows conductance. Inset shows a coomassie-stained gel of the main 
elution peaks (i, and ii). “1” indicates SpaO(145-213) and “2” indicates 
SpaO(232-297). Peak “i” from the SourceQ elution was isolated from peak “ii” 
and further purified by size exclusion chromatography (Superdex75, right). Inset 
abbreviations are the same as those in the inset at left.
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Figure 2.13: Diffraction analysis of SpaO(145-213) + SpaO(232-297). (A) 
Crystals of SpaO(145-213) + SpaO(232-297). (B) Representative diffraction 
image of SpaO(145-213) + SpaO(232-297) crystals with the edge resolution 
indicated. (C) Stereoimage of a selected region of the 2Fo-Fc electron density 
map for the 2.9 Å SpaO(145-213) + SpaO(232-297) structure. The map is 
contoured to 1σ and clipped to within 2 Å of the peptide for clarity.  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Data       
Collection
Space group P41212 P41212
Cell: a, b, c (Å) 66.38, 66.38, 95.21 65.76, 65.76, 95.65
Cell: α, β, γ (°) 90, 90, 90 90, 90, 90
Resolution (Å) 46.94–3.00 (3.18–3.00) 38.68–2.9 (3.08–2.9)
Rmerge 0.221 (1.463) 0.166 (1.447)
I/σI 11.8 (3.1) 14.4 (2.7)
CC1/2 0.989 (0.839) 0.996 (0.856)
Completeness (%) 100 (100) 99.3 (99.3)
No. of reflections 4,653 4,964


















B factors: Protein 74.20
B factors: Ligand/ion 105.00
B factors: Water  
Geometry (r.m.s.d.)
Bond lengths (Å) 0.010
Bond angles (°) 1.33
[Φ,Ψ] Favored (%) 89
[Φ,Ψ] Allowed (%) 97
[Φ,Ψ] Outliers (%) 3
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Structure determination confirmed the presumptive SPOA1 region as having a 
bond fide SPOA fold. SPOA1 and SPOA2 form a distinct, heterotypic SPOA-
SPOA interaction with an overall topology similar to that observed in SPOA2 
homodimers and a similar interfacial area (1799 Å2). The SPOA1 backbone 
follows that of the prototypical SPOA fold, retaining the antiparallel beta-sheet 
floor and fingers-to-palm architecture (Figure 2.14A,B). 
SPOA1-SPOA2 and the SPOA2 homodimer superpose with 2.47 Å 
r.m.s.d. (Figure 2.14C). The overall topology of SPOA2 in association with 
SPOA1 is grossly similar to that seen in the homodimer (Figure 2.13D, r.m.s.d. 
1.67 Å), but with some conformational alteration. In context, each thumb in the 
SPOA1-SPOA2 complex is rotated clockwise towards its adjacent fingers relative 
to the thumb positions in the SPOA2 homodimer (Figure 2.14E,F), creating a 
shallower, less tall structure. To accommodate the SPOA1 thumb in this 
orientation, the SPOA2 fingers are displaced relative to their position in the 
homodimer. This displacement is the largest for the amide nitrogen of L256 (5.7 
Å, Figure 2.14F). 
To confirm that SPOA1 and SPOA2 interact outside of the solid-phase 
crystalline environment, I re-evaluated previously acquired NMR data in the 
context of the crystal structure. A post hoc analysis of the 15N-NOESY-HSQC 
spectrum for SpaO(140-297) revealed long-range amide proton correlations 
between SPOA1 and SPOA2 (Figure 2.15), consistent with association of the two 
SPOAs in solution.
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Figure 2.14: Structure of the SpaO SPOA1-SPOA2 interaction. (A) Ribbon 
diagram of the SpaO(145-213) + SpaO(232-297) crystal structure. 
SpaO(145-213) is shown in cyan and SpaO(232-297) is shown in green. The 
structure is annotated as SPOA diagrams previously shown; asterisk indicates 
the β-sheet “floor.” (B) Topology diagram for the structure in (A) generated using 
Pro-Origami. (C) SpaO(145-213, cyan) + SpaO(232-297, green) superposed on 
the SpaO(232-297, gray) homodimer. (D) SpaO SPOA2 from the SPOA1-SPOA2 
model (green) superposed in isolation on one protomer of the SPOA2 
homodimer model (gray). (E,F) Worm diagrams derived from the alignment in (C) 
highlighting the displacement of the SPOA1 and SPOA2 thumbs relative to the 
thumb positions in the homodimer (orange arrows). The maximum displacement 
in the fingers region of SPOA2 is highlighted in red.  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Figure 2.14: Structure of the SpaO SPOA1-SPOA2 interaction. 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Figure 2.15: NOESY data support a SPOA1-SPOA2 interaction. (A) 
Schematic illustration of the SPOA1-SPOA2 crystal structure with regions for 
further analysis indicated. (B) Protons were modeled on the SPOA1-SPOA2 
structure using ReadySet in Phenix. Inter-proton distances are specified for 
selected inter-domain long-range amide proton correlations observed in the 15N-
NOESY-HSQC spectrum. (C-E) Protonated backbone models for the regions 
specified in (A) are shown at left with residues of interest noted. In the 15N-
NOESY-HSQC spectra at right, the diagonal-peaks are indicated by red asterisks 
and the cross-peaks by red dotted lines.  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Figure 2.15: NOESY data support a SPOA1-SPOA2 interaction.
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2.5 Do SPOA1-SPOA2 interactions facilitate SpaO oligomerization?
The structural characterization of the SPOA1-SPOA2 interaction suggests a 
potential mechanism for the higher order assembly of a high molecular weight 
sorting platform: interacting protein regions covalently linked in a polypeptide 
chain can interact in cis (and remain monomeric) or can form higher order 
oligomers by interacting in trans (Figure 2.16). Given the less than 20 residue 
linker connecting SPOA1 and SPOA2, they would experience a low millimolar-
range relative concentration and would likely interact in an intramolecular 
fashion. However, at high local SpaO concentrations in association with the 
T3SS, intermolecular heterotypic SPOA interactions might dominate, perhaps 
forming fibrils or annuli and explaining the apparent oligomeric nature of the 
sorting platform. Indeed, a similar model of intermolecular domain swapping was 
recently suggested for the ring-forming injectisome protein PrgK (45).
Hypothetical SpaO oligomerization driven by intermolecular heterotypic 
SPOA interactions would be dependent on the covalent linkage of SPOA1 and 
SPOA2. Dynamic light scattering analysis of co-refolded SPOA1 and SPOA2 
revealed a hydrodynamic radius (22 Å ± 1 Å) and predicted molecular weight (21 
kDa ± 3 kDa) most consistent with a single heterodimer (expected molecular 
weight: 16 kDa), as would be expected in the absence of a covalent linker 
(Figure 2.16). Similarly, even at 1mM concentration, SpaO(140-297) was 
monodispersed and non-oligomeric (hydrodynamic radius: 24 Å ± 1 Å; calculated 
mass: 26 kDa ± 3 kDa; expected mass: 18 kDa), suggesting that the presence of 
the linker does not promote intermolecular SPOA-SPOA interactions and 
 68
oligomerization (Figure 2.16). The small increase in hydrodynamic radius relative 
to co-refolded SPOA1-SPOA2 is most likely the result of the unstructured linker 
projecting from the globular core, and is not consistent with high-order 
oligomerization, where one would expect a very large increase in hydrodynamic 
radius and calculated molecular weight. This finding is also consistent with the 
size exclusion chromatography profile of SpaO(140-297), which shows a lack of 
aggregation (Figure 2.9).
Figure 2.16: Hypothetical models of SPOA interactions in cis and trans. (A) 
Schematic models for putative intra- and intermolecular SPOA1-SPOA2 
interactions and their implications for the SpaO oligomerization state. 1 and 2 
indicate the SpaO SPOA1 and SPOA2, respectively, and N indicates the SpaO 
amino-terminal domain(s). (B) DLS analysis of SPOA1-SPOA2 with (right) and 
without (left) the inter-SPOA linker. Regularization graph shown.  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However, one might counter that perhaps some in vivo factor promotes 
intermolecular SPOA-SPOA interactions (e.g. association with the T3SS basal 
body or export apparatus). Thus, I tested whether genomic deletion of the SpaO 
amino-terminal domain and SPOA1 can be complemented in trans, as assayed 
by S. typhimurium T3SS secretory function. When grown under T3SS stimulating 
conditions, the culture supernatant of S. typhimurium has a stereotyped protein 
composition, consisting of both flagellar and injectisome secretion substrates 
(Figure 2.17; secreted proteins are annotated as per Aizawa and colleagues 
(87)). Deletion of spaO results specifically in the loss of injectisome-dependent 
secretory products from the culture supernatant, and deletion of spaO codons 
1-203 phenocopies spaO deletion, indicating that the SpaO amino-terminal 
domain(s) and/or SPOA1 are necessary for T3SS function (Figure 2.17). 
Because SpaO(1-219) is able to complement the deletion of spaO codons 1-203 
(Figure 2.17, red asterisks), the covalent linkage of SPOA1 and SPOA2 is not 
necessary for T3SS function. While this does not rule out the presence of 
intermolecular heterotypic SPOA interactions in vivo, if they do occur, they are 
not explicitly necessary for secretion. It should be noted that SpaO(1-219) does 
not complement a full genomic deletion of spaO, demonstrating that SPOA2 is 
also necessary for T3SS function (Figure 2.17). Similarly, insertion of a double 
stop codon after spaO codon 219 abrogates T3SS (Figure 2.17). The successful 
expression of all SpaO genomic domain deletions and complementation 
plasmids was confirmed by western blot (Figure 2.18).
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Figure 2.17: Covalent linkage of SPOA1 and SPOA2 is not necessary for 
T3SS function. (A) Coomassie-stained SDS-PAGE of S. typhimurium culture 
supernatants grown under T3SS stimulating conditions (0.3M NaCl, strain 
SB1741). Bands previously identified by Aizawa and colleagues (87) are noted 
and color-coded by T3SS subtype – injectisome in red, flagellar in blue. (B) 
Coomassie-stained SDS-PAGE of S. typhimurium culture supernatants grown 
under T3SS stimulating conditions. Red asterisks indicate injectisome-specific 
secretion substrates. Abbreviations: WT, wild-type; ΔO, deletion of spaO; 
Δ1-203, deletion of spaO codons 1-203; 1-219, complementation with 
SpaO(1-219); 1-219stop, insertion of two stop codons following spaO codon 219. 
SpaO was 3xFLAG tagged at its amino terminus in each S. typhimurium strain 
(except ΔO) and complementation construct. The first two lanes of (A) and (B) 
are from the same image, truncated in (A) to allow annotation.
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Figure 2.18: SpaO deletion mutants and complementation plasmids. (A, B) 
Anti-FLAG western blots of SDS-PAGE separated S. typhimurium whole cell 
lysates. (A) Strains carrying amino-terminal 3xFLAG fusions to SpaO with the 
indicated stop codon insertions or domain deletions. ∆O denotes a strain carrying 
a full deletion of SpaO, which lacks a 3xFLAG insertion and serves as a negative 
control. (B) ∆O strain complemented with the indicated SpaO expression 
plasmids. All expression constructs are amino-terminal 3xFLAG fusions.  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CHAPTER 3: 
SpaO SPOA1-SPOA2 FORMS A PLATFORM FOR THE OrgB APAR
If heterotypic SPOA1-SPOA2 interactions do not function to create higher order 
SpaO oligomers, what might be the function of this novel type of SPOA-SPOA 
interaction? I hypothesized that this interaction might function in sorting platform 
assembly by interacting with other sorting platform components. This chapter 
describes the identification and structural characterization of a binding partner for 
SpaO SPOA1-SPOA2. 
3.1 Partial reconstitution of the SPI-1 sorting platform
Seminal work by Galán and colleagues (129) combined co-immunoaffinity 
purification of SpaO and its binding partners from S. typhimurium with mass 
spectrometric proteomic analysis to identify the majority constituents of the SPI-1 
T3SS sorting platform. The proteins InvC (SctN, ATPase), OrgB (SctL, “ATPase 
regulator”), and OrgA (SctK, function unknown) robustly co-purified with SpaO. To 
probe these interactions more precisely, I attempted to reconstitute the core 
sorting platform by heterologous coexpression in E. coli.
Double hexahistidine-tagged SpaO is able to co-affinity purify the sorting 
platform components OrgB and InvC when co-expressed in E. coli (Figure 3.1A). 
Formation of the SpaO-OrgB-InvC termary complex is OrgB-dependent, as SpaO 
alone is insufficient to co-affinity purify InvC (Figure 3.1A). In fact, SpaO interacts 
directly with OrgB, as InvC is dispensible for SpaO-OrgB complex formation 
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(Figure 3.1B). Expression of the cryptically translated SpaO carboxy-terminal 
fragment is not necessary for SpaO-OrgB interaction, as SpaO(ValGTT203) was 
sufficient to co-affinity purify OrgB (Figure 3.1B). Interestingly, as with full length 
SpaO alone, loss of the free, SPOA2-containing carboxy-terminal fragment 
resulted in substantially lower soluble yields.
Figure 3.1: SpaO interacts directly with OrgB to form a SpaO-OrgB-InvC 
ternary complex. (A) Coomassie-stained gel of protein elution from NiNTA resin 
(top) following coexpression of double hexahistidine (12HIS)-tagged SpaO (“FL,” 
full length) or SpaO(140-297, ValGTT203) with the indicated sorting platform 
constituents (InvC and/or OrgB). Below, whole cell lysates from the same 
preparations allow confirmation of the intended constituents’ expression. Asterisk 
denotes nonspecific co-purifying E. coli proteins, likely chaperones. SpaOc 
indicates the cryptically expressed SPOA2-containing carboxy-terminal fragment. 
(B) Coomassie-stained gel of protein elution from NiNTA resin (top) following 
coexpression of OrgB and double hexahistidine (12HIS)-tagged, full length SpaO 
with the indicated codon 203 genotype. Below, whole cell lysates from the same 
preparations allow confirmation of the intended constituents’ expression. Asterisk 
denotes nonspecific co-purifying E. coli proteins, likely chaperones. SpaOc 
indicates the cryptically expressed SPOA2-containing carboxy-terminal fragment.
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Figure 3.1: SpaO interacts directly with OrgB to form a SpaO-OrgB-InvC 
ternary complex.
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Coexpression of double hexahistidine-tagged SpaO with OrgA did not result in 
co-affinity purification of the two species and presumptive OrgA expression was 
particularly low (Figure 3.2A). Additional coexpression of InvC or InvC-OrgB did 
not enhance OrgA expression levels or result in co-affinity purification of OrgA 
(Figure 3.2B). OrgA could be robustly expressed in E. coli as a double 
hexahistidine fusion and purified under denaturing conditions (Figure 3.2C), but 
could not be solubly refolded.
Figure 3.2: Attempts to incorporate OrgA into SpaO containing complexes 
were unsuccessful. (A) Coomassie-stained gel of protein elution from NiNTA 
resin (left) following coexpression of double hexahistidine (12HIS)-tagged SpaO 
with the indicated sorting platform constituents (InvC and/or OrgA). At right, 
whole cell lysates from the same preparations allow confirmation of the intended 
constituents’ expression. SpaOc indicates the cryptically expressed SPOA2-
containing carboxy-terminal fragment. (B) Coomassie-stained gel of protein 
elution from NiNTA resin (left) following coexpression of double hexahistidine 
(12HIS)-tagged InvC with the indicated sorting platform constituents. At right, 
whole cell lysates from the same preparations allow confirmation of the intended 
constituents’ expression. Red asterisk denotes presumptive OrgA expression. (C) 
OrgA can be robustly overexpressed in E. coli as a double hexahistidine fusion, 
but it is not soluble when purified under native conditions. L, ladder; WCL, whole 
cell lysate; E, NiNTA elution after purification under native conditions; UE, NiNTA 
elution after purification under denaturing conditions.
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Figure 3.2: Attempts to incorporate OrgA into SpaO containing complexes 
were unsuccessful.
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Given the biochemical intractability of OrgA, I decided to focus my efforts on the 
SpaO-OrgB-InvC subset of the sorting platform. I hypothesized that the SPOA1-
SPOA2 module might serve as a scaffold for the interaction of SpaO with OrgB-
InvC. Indeed, SpaO(140-297) is sufficient to co-affinity purify OrgB-InvC (Figure 
3.1A). This construct also contains the ValGTT203 mutation, further demonstrating 
that the SPOA2 homodimer is dispensable for SpaO-OrgB-InvC complex 
formation.
OrgB and its homologues are predicted to share a common amino-
terminal organization: a disordered region followed by a coiled coil (Figure 3.3A). 
In the flagellar system, the unstructured region at the amino terminus of the OrgB 
homologue FliH is necessary for its interaction with the SpaO homologues FliM 
and FliN (133). Similarly, deletion of the pre-coiled-coil residues (1-30) of OrgB 
prevented the formation of the SpaO-OrgB-InvC ternary complex (Figure 3.3B). 
Of note, these residues were dispensable for the interaction of OrgB with InvC 
(Figure 3.3B), consistent with the work of Dr. Mirjana Lilic (Laboratory of 
Structural Microbiology, Rockefeller University) and previously published yeast 
two hybrid data from Shigella (182). The amino-terminal 30 residues of OrgB 
were by themselves sufficient to interact with SPOA1-SPOA2 of SpaO. 
OrgB(1-30) could be expressed as a fusion to human thioredoxin and co-refolded 
with SpaO(140-297). After cleavage of the thioredoxin carrier from the OrgB 
peptide, OrgB(2-30) co-eluted with SpaO(140-297) from a size exclusion column 
(Figure 3.3D). 
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Figure 3.3: The OrgB amino terminus is necessary and sufficient to mediate 
the interaction with SpaO SPOA1-SPOA2. (A) COILS analysis of OrgB. 
Likelihood of coiled coil formation is assessed by the program COILS. Different 
scanning window sizes are indicated by line color: 14 residues, green; 21 
residues, blue; 28 residues, red. CC indicates the presumed coiled coil region. 
Asterisk highlights the region amino-terminal to the CC. (B) Coomassie-stained 
gel of protein elution from NiNTA resin (top) following coexpression of double 
hexahistidine (12HIS)-tagged InvC with the indicated sorting platform 
constituents. FL denotes full length OrgB(1-226) and ∆30 denotes OrgB(31-226). 
Below, whole cell lysates from the same preparations allow confirmation of the 
intended constituents’ expression. Red asterisk denotes SpaO expression. (C) 
SpaO(140-297) and Trioredoxin(Trx)::OrgB(2-30) purified under denaturing 
conditions for co-refolding. (D) Co-refolded, 3C protease-cut SpaO(140-297) in 
complex with OrgB(2-30) can be separated from free Trx and affinity tags by size 
exclusion chromatography. RF+3C indicates co-refolded material after 3C 
cleavage, but before further purification. The main size exclusion 
chromatography peaks are denoted i and ii. 
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Figure 3.3: The OrgB amino terminus is necessary and sufficient to mediate 
the interaction with SpaO SPOA1-SPOA2.
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3.2 Structure of the SpaO(SPOA1-SPOA2)-OrgB(APAR) complex
Herein, I will refer to the SpaO-binding region at the amino terminus of OrgB and 
its homologues as the Adaptor Peptide of the ATPase Regulator (APAR). What is 
the structural basis for this interaction? In order to characterize the SPOA1-
SPOA2-APAR interaction by X-ray crystallography, I attempted to crystallize 
complexes of the OrgB APAR peptide and SpaO(SPOA1-SPOA2), but they were 
resistant to crystallization. 
Fusion of readily crystallizable proteins to target proteins has been used to 
enhance target crystallization (183), most notably in the case of T4 lysozyme 
fusions to various GPCRs (184, 185). To explore whether this strategy might 
promote crystallization of the SpaO-OrgB complex, I fused the pre-coiled-coil 
region of OrgB (residues 1-30) to T4 lysozyme and found that it still bound to 
SpaO(140-297) (Figure 3.4A). Consistent with the finding that the SPOA2 
homodimer was not necessary for the SpaO-OrgB interaction, OrgB(1-30)::T4 
lysozyme did not pull down SpaO SPOA2 homodimers (Figure 3.4A). The 
Org(1-30)::T4 lysozyme fusion formed a complex with SpaO(145-213) + 
SpaO(232-297) that was stable over size exclusion chromatography (Figure 
3.4B), and this complex was subjected to crystallization screening. The 
SpaO(SPOA1-SPOA2)-OrgB(APAR)::T4 lysozyme complex was crystallized, its 
structure solved by molecular replacement using the SpaO(145-213) + 
SpaO(232-297) model and a known T4 lysozyme model (PDB 2LZM), and the 
structure refined to 2.0 Å resolution (Figure 3.5 and Table 3.1).
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Figure 3.4: Expression and purification of SpaO(145-213) + SpaO(232-297) + 
OrgB(1-30)::T4lysozyme. (A) OrgB(1-30) fused to hexahistidine-tagged T4 
lysozyme (APAR::T4::6HIS) was mixed with the indicated SpaO constructs and 
passed over NiNTA resin. Coomassie-stained gels of the input and imidazole 
elution are shown. (B) Purification of the SpaO(145-213) + SpaO(232-297) + 
OrgB(1-30)::T4 lysozyme complex. OrgB(1-30)::T4 lysozyme (BT4) purified 
under denaturing conditions (E) was refolded and purified by cation exchange 
chromatography (i) after removal of affinity tags by 3C protease. Cation 
exchange purified material was complexed with an excess of SpaO(145-213) + 
SpaO(232-297) (“1” and “2”, respectively) and the ternary complex (ii) separated 
from excess SpaO(145-213) + SpaO(232-297) (iii) by size exclusion 
chromatography.
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Figure 3.5: Diffraction analysis of SpaO(145-213) + SpaO(232-297) + 
OrgB(1-30)::T4lysozyme. (A) Crystals and (B) diffraction pattern for 
SpaO(145-213) + SpaO(232-297) + OrgB(1-30)::T4lysozyme. Edge resolution for 
diffraction image is indicated. (C) Stereoimage of a selected region of the 2Fo-Fc 
electron density map for the 2.0 Å SpaO(145-213, cyan) + SpaO(232-297, green) 
+ OrgB(1-30)::T4 lysozyme (gray) structure. The map is contoured to 1σ.
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Table 3.1: Diffraction and refinement statistics for SpaO(145-213) + 
SpaO(232-297) + OrgB(1-30)::T4lysozyme.
  Native SeMet SpaONative OrgB::T4
PDB ID 4YX7 4YXA
Data       
Collection
Space group P21 P21
Cell: a, b, c (Å) 62.092, 89.07, 62.092 62.88, 88.5, 63.32
Cell: α, β, γ (°) 90, 114.94, 90 90, 116.07, 90
Resolution (Å) 47.59–2.0 (2.05–2.0) 45.8–2.35 (2.43–2.35)
Rmerge 0.102 (0.530) 0.088 (0.617)
I/σI 10.5 (3.2) 12.8 (2.6)
CC1/2 0.994 (0.828) 0.997 (0.816)
Completeness (%) 99.5 (99.8) 99.0 (99.6)
No. of reflections 41,183 25,740
Redundancy 5.1 (5.2) 6.6 (6.6)
Refinement
Rwork/Rfree 0.1571/0.2096 0.1984/0.2618




B factors: Protein 33.10 46.90
B factors: Ligand/ion    
B factors: Water 39.60 45.60
Geometry (r.m.s.d.)
Bond lengths (Å) 0.008 0.011
Bond angles (°) 1.16 1.46
[Φ,Ψ] Favored (%) 94 89
[Φ,Ψ] Allowed (%) 99.2 98.2
[Φ,Ψ] Outliers (%) 0.8 1.8
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The crystallographic asymmetric unit contained two copies of the complex in 
nearly identical conformations (superposed with 0.81 Å r.m.s.d., Figure 3.6), so 
only one constituent complex will be described in the following analyses. A 
cursory analysis of the crystal architecture highlights the importance of the 
construct modifications used to enhance crystallization. Deletion of the inter-
SPOA linker peptide appears to have allowed favorable packing within the 
asymmetric unit: the two SPOA1-SPOA2 dimers pack against each other’s 
“bottom” face, where the linker peptide might normally be positioned. 
Furthermore, the T4 lysozyme fusion chaperones form multiple packing 
interfaces with both SpaO and other T4 lysozyme molecules (Figure 3.6)
Within each constituent SpaO-OrgB complex, the OrgB APAR forms a 
lariat-like structure, contacting the thumb of SPOA2 and fingers of SPOA1 
(Figure 3.7). OrgB makes substantial contact with both SPOA1 and SPOA2 of 
SpaO, burying 570 Å2 against SPOA1 and 470 Å2 against SPOA2, consistent 
with the finding that both SPOAs are required for the SpaO-OrgB(APAR) 
interaction (e.g. that SPOA2 alone is insufficient, Figure 3.4A). In the APAR-
bound structure, there is little change in the conformation of SpaO (Figure 3.7, 
1.01 Å r.m.s.d.). To confirm the crystallographic model, crystals grown with 
SeMet-doped SpaO (but native OrgB::T4 lysozyme) were subjected to diffraction 
analysis (Table 3.1).  The structure was solved by molecular replacement using 
the all-native structure and anomalous scatterer positions were determined using 
ANODE (186). Six pronounced anomalous density peaks were observed in the 
asymmetric unit, spatially corresponding to the three structured Met residues in 
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each SPOA2 (Figure 3.8), further confirming the arrangement and stoichiometry 
of SPOA domains in the structure.
Figure 3.6: Asymmetric unit and crystal packing of the SpaO(SPOA-
SPOA2)-OrgB(APAR) complex. (A) The asymmetric unit of the SpaO(145-213, 
cyan) + SpaO(232-297, green) + OrgB(1-30)::T4 lysozyme (gray) crystal contains 
two copies of the SpaO-OrgB complex. (B) Superposition of the two constituent 
complexes in the asymmetric unit of the crystal showing their architectural 
similarity (0.81 Å r.m.s.d.). (C,D) Qualitative analysis of crystal packing reveals 
that T4 lysozyme is involved in contacts with SpaO (C) and with itself (D). (C, red 
dashed box) Two copies of SpaO surrounded by T4 lysozyme molecules (3 
shown). (D, red dashed box) T4 lysozyme molecule sandwiched between two 
other T4 lysozyme molecules.  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Figure 3.7: Crystal structure of the SpaO(SPOA1-SPOA2)-OrgB(APAR) 
complex. (A) Ribbon diagram of the SpaO-OrgB crystal structure. For simplicity, 
the T4 lysozyme crystallization chaperone has been omitted and only one of the 
two constituent complexes from the crystallographic asymmetric unit is shown. 
The amino- and carboxy-termini of the OrgB APAR are denoted as “N” and “C,” 
respectively. (B) Surface representation of the complex in (A). The OrgB APAR 
(gray mesh) contacts both SpaO SPOA1 (cyan) and SPOA2 (green). (C) 
Superposition of the apo- (cyan/light green) and APAR-bound (blue/dark green) 
forms of SpaO (1.01 Å r.m.s.d.). 
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Figure 3.8: ANODE confirmation of SPOA positioning and stoichiometry in 
the SpaO(SPOA1-SPOA2)-OrgB(APAR) complex. ANODE analysis of the 
anomalous signal in the SpaO(SPOA1-SPOA2)-OrgB(APAR)::T4 lysozyme 
complex generated by SeMet substitution in SpaO (but not OrgB::T4 lysozyme). 
The anomalous signal (violet, contoured at 8 e/Å3) localizes to the three 
structured SeMet in each copy of SpaO(232-297), providing empirical 
confirmation of the SpaO-OrgB model coordinates and stoichiometry. The image 
was created in COOT. Red crosses are structured solvent.
Independent NMR analyses of SpaO(140-297) bound to OrgB(APAR) in solution 
are consistent with the interface defined in the crystal (Figure 3.9). 151 out of 155 
possible amide proton resonances were assigned for APAR-bound 
SpaO(140-297). Changes in amide proton chemical shift upon APAR binding 
were calculated as the magnitude of weighted Euclidean vectors (see Chapter 7). 
Compared to apo-SpaO, the largest chemical shift deviations (CSD) of backbone 
amide resonances in SpaO-OrgB occur in two major clusters along the SpaO 
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primary structure — one each in SPOA1 and SPOA2 (Figure 3.9). These 
residues map on the crystal structure as a single surface patch at the SpaO-
OrgB interface (Figure 3.9). It should be noted that the NMR data suggest that 
the inter-SPOA linker is not directly involved APAR-binding (Figure 3.9), an 
assertion that was impossible to make using the linker-free crystallographic 
model. 
Additional NMR analyses allowed me to rule out interactions between 
SpaO(SPOA1-SPOA2) and the APAR-adjacent coiled coil region of OrgB. The 
HSQC of SpaO(140-297) bound to OrgB(1-70), which contains both the APAR 
and coiled coil regions, was grossly similar to that of SpaO bound to the OrgB 
APAR alone (Figure 3.10A), suggesting that the OrgB coiled coil does not make 
additional contacts with SpaO upon APAR binding. The few differences between 
the OrgB(2-30)- and OrgB(1-70)-bound SpaO HSQCs map to the region of SpaO 
binding the OrgB amino terminus, which differed between these two constructs 
because of divergent cloning scars (Figure 3.10B). Indeed, the HSQC of SpaO 
bound to OrgB(1-70) was indistinguishable from that of SpaO bound to 
OrgB(1-30) fused to an inert carrier (the cyan fluorescent protein variant 
Cerulean), in which both OrgB amino-termini were identical Figure 3.10C).
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Figure 3.9: Solution NMR data support the crystallographic model of the 
SpaO(SPOA1-SPOA2)-OrgB(APAR) complex. (A) Overlayed 15N-HSQC of 
apo- (green) and APAR-bound- (violet) SpaO(140-297). The five largest peak 
shifts are noted. (B) Chemical shift deviations (CSD) for apo- vs. APAR-bound-
SpaO(140-297). Note that the unstructured linker is residues 214-231. (C) The 
solution interaction data from (A, B) are mapped onto the SpaO-OrgB crystal 
structure. Surface residues are color coded by the size of their weighted CSD in 
units of standard deviation. Residues not assigned an amide resonance in one of 
the two data sets are left white. The same view of SpaO is shown without (top) 
and with (bottom) the OrgB APAR (gray surface).
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Figure 3.10: The OrgB coiled coil region does not interact with 
SpaO(SPOA1-SPOA2). (A) Overlayed 15N-HSQC of APAR-coiled-coil-bound- 
(B(1-70), green) and APAR-bound- (B(2-30), violet) SpaO(140-297). (B) The 7 
residues (red) with the most perturbed resonances in (A) are clustered around 
the OrgB amino-terminal 5 residues (green) in the SpaO-OrgB crystal structure. 
(C) The amide proton resonances of SpaO(140-297) bound to OrgB(1-30):: 
Cerulean is indistinguishable from that bound to OrgB(1-70). Zoomed 15N-HSQC 
highlighting concordance at HN/G200 is shown. HN/G200 was one of the 7 
resonances discordant between OrgB(2-30)- and OrgB(1-70)-bound SpaO.
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The SpaO residues that make up the core of the OrgB-binding interface are 
highly conserved across both the Salmonella/Shigella and Yersinia/
Pseudomonas T3SS clades (Figure 3.11A,B). In the crystal, a subset of these 
residues form the hydrophobic docking site for the aliphatic side chains of OrgB 
residues Ile17, Leu18, and Ile19 (Figure 3.11D). The OrgB surface area buried by 
these three residues (360 Å2) accounts for approximately one third of the APAR’s 
total buried area. Here, the APAR shows noteworthy sequence homology: 
immediately following a conserved glycine (Gly16, pseudo-lariat apex) is a string 
of aliphatic and basic amino acids in each homologue (Figure 3.11C). The 
sequence conservation on both sides of the SpaO-OrgB interface suggests that 
this mode of binding is generally applicable to other injectisome systems.
Figure 3.11: Generalizability of the SPOA1-SPOA2-APAR model. (A) The 
SpaO residues at the APAR interaction site are highly conserved across 
homologues in other species. Excerpts of the M-COFFEE alignment of SpaO, S. 
flexneri Spa33, Y. enterocolica YscQ, and P. aeruginosa PscQ are shown with 
conserved APAR-interacting residues highlighted in red. Asterisk denotes 
identity; colon, high conservation; period, low conservation. (B) A surface 
representation of SpaO with the 100% or highly conserved interfacial residues 
identified in (A) colored red and the OrgB APAR backbone is yellow. (C) Clustal 
Omega alignment of the APAR regions of OrgB, S. flexneri MxiN, Y. enterocolica 
YscL, and P. aeruginosa PscL. Color code: Aliphatic/aromatic, black; basic, blue; 
acidic, red; polar/gylcine, green. (D) The binding site for OrgB(17-19, gray) is 
shown as an electrostatic surface. OrgB(1-15) have been removed for clarity.  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Figure 3.11: Generalizability of the SPOA1-SPOA2-APAR model.
To quantitatively assess the thermodynamic parameters of the SpaO-
OrgB(APAR) interaction, the binding of SpaO(140-297) to OrgB(1-30)::Cerulean 
was probed by isothermal titration calorimetry (ITC). At 25°C, SpaO(140-297) 
bound to the APAR peptide with a dissociation constant of 2.0 µM ± 0.5 µM at 
1.04 ± 0.01 sites (Figure 3.12). No binding was observed between 
SpaO(140-297) and Cerulean without the APAR fusion.  Providing additional 
support for the necessity of SPOA1 in APAR binding, no specific binding was 
observed between the SPOA2 homodimer and OrgB(1-30)::Cerulean (Figure 
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3.12). The interaction between the APAR and SpaO(140-297) was endothermic 
and entropy driven (∆H = 1602 ± 71 cal/mol; ∆S = 31.5 ± 0.3 cal/mol/deg), 
consistent with the importance of hydrophobic interactions at the interface.
Figure 3.12: Quantitative assessment of SpaO(SPOA1-SPOA2)-OrgB(APAR) 
binding thermodynamics. Representative ITC data for the OrgB APAR 
interacting with SpaO SPOA1-SPOA2 (left) and SPOA2 alone (right). The 
uncorrected power differential between the reference and sample cells is shown 
on top; the background subtracted heats are shown on the bottom.
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3.3 SPOA-APAR interaction is necessary for T3SS function
To test whether the SPOA1-SPOA2-APAR interaction per se is necessary for 
T3SS function, I sought to construct an APAR mutant that would disrupt SpaO 
binding. The crystallographic model and binding thermodynamics suggested that 
mutation of OrgB(17-19) from aliphatic to charged residues (I17D,L18D,I19D) 
would disrupt the the SpaO-OrgB interface. As predicted, SpaO failed to co-
affinity purify OrgB(I17D,L18D,I19D)-InvC when co-expressed in E. coli (Figure 
3.13A). Notably, the triple mutation did not impair OrgB solubility or affect InvC 
binding (Figure 3.13B). In vivo, the aspartate triple mutation completely abolished 
T3SS secretory function (Figure 3.13C), consistent with the hypothesis that the 
SpaO(SPOA1-SPOA2)-OrgB(APAR) interaction is necessary for T3SS function. 
Fluorescence microscopic analyses of the Yersinia SpaO homologue have 
shown it to localize in discrete perimembranous punctae (137). Might the 
SPOA1-SPOA2-APAR interaction function to localize SpaO to the bacterial inner 
membrane? In an otherwise wild-type genomic background, an EGFP::
3xFLAG::SpaO fusion exhibits punctate, perimembranous localization, consistent 
with its recruitment to injectisome basal body channels (Figure 3.13D). Deletion 
of orgB disrupts proper SpaO localization, producing a more diffuse, cytoplasmic 
pattern, and the asparate triple mutation was sufficient to phenocopy the orgB 
deletion mutant (Figure 3.13D). Together, these data suggest that the SPOA1-
SPOA2-APAR assembly is necessary for the proper localization of SpaO to 
discrete perimembranous puncta, and that this arrangement is required for T3SS 
function.
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Figure 3.13: Structure based disruption of the SpaO(SPOA1-SPOA2)-
OrgB(APAR) interaction disrupts T3SS function and SpaO subcellular 
localization. (A) Co-affinity purification of double hexahistidine-tagged SpaO 
with InvC and OrgB (WT, wildtype; 3xD, I17D/L18D/I19D) coexpressed in E. coli. 
Coomassie-stained gel is shown. Asterisk denotes nonspecific co-purifying E. coli 
proteins, likely chaperones. SpaOc indicates the cryptically expressed SPOA2-
containing carboxy-terminal fragment. (B) Co-affinity purification of double 
hexahistidine-tagged InvC and 3xD OrgB. (C) Coomassie-stained culture 
supernatant from wild-type (WT, strain SB1741), orgB deletion(Δ) and 
orgB(I17D,L18D,I19D) (3xD) S. typhimurium shows loss of injectisome substrate 
(red asterisks) secretion in the mutants, while flagellar secretion remains intact. 
(D) Widefield microscopic imaging of fixed S. typhimurium shows exclusive 
perimembranous localization of EGFP::3xFLAG::SpaO in the wild type 
background but cytoplasmic localization in the orgB mutants (scale bar is 2 µm, 
single z-slices shown). Nile red is used as a membrane stain.
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Studies of the flagellar apparatus suggest an intriguing alternate function for the 
APAR region of OrgB.  In the flagellar system, the extreme amino terminus of the 
OrgB homologue FliH has been shown to be necessary for proper localization of 
the FliH-FliI (InvC homologue) complex to the flagellar T3SS export apparatus 
(133). Photocrosslinking studies place the FliH amino terminus in close proximity 
to the export apparatus protein FlhA (InvA homologue), but evidence for a direct 
interaction is weak (187). Might the APAR of OrgB interact with the cytoplasmic 
domain of InvA? One might imagine a scenario where APARs extending from 
OrgB-InvC complexes are able to interact with both SpaO and InvA, bridging the 
sorting platform and export apparatus. However, while double hexahistidine-
tagged SpaO(140-297) could co-affinity purify OrgB(1-30)::Cerulean, no 
interaction between double hexahistidine tagged InvA(cytoplasmic domain) and 
OrgB(1-30)::Cerulean was observed (Figure 3.14).
Figure 3.14: The OrgB APAR does not interact with the InvA cytoplasmic 
domain. Co-affinity purification of OrgB(1-30)::Cerulean with the indicated 
double hexahistidine tagged proteins shows that the OrgB APAR does not 
interact with the cytoplasmic domain of InvA in isolation.  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CHAPTER 4:
SPOA-APAR INTERACTIONS IN THE FLAGELLAR T3SS
4.1 SPOA-APAR interactions are T3SS subtype specific
As described above, S. typhimurium contains three T3SS: two injectisomes and a 
flagellar apparatus. The flagellar structural analog of the the sorting platform is a 
robust annulus of density at the cytoplasmic face of the flagellar basal body. This 
“C-ring” is primarily composed of three proteins: FliM, FliN, and FliG (188). The 
SpaO homologues FliM and FliN are predicted to contain one SPOA domain 
each, which I prospectively designate as SPOA1 and SPOA2, respectively 
(Figure 4.1). Paralleling the injectisome, FliN is known to interact with the OrgB 
homologue FliH (133). The evolutionary relationship between injectisomes and 
flagella creates a practical conundrum: how are homologous T3SS components 
segregated to their corresponding secretion systems within a common 
cytoplasmic milieu? 
To qualitatively assess the subtype specificity of SPOA-APAR interactions, 
I co-affinity purified a panel of Salmonella SPOA domains with hexahistidine-
tagged APAR::T4 lysozyme fusions (Figure 4.2). Indeed, the OrgB and FliH 
APARs robustly co-affinity purify their cognate SPOA1-SPOA2 proteins but not 
that of the other T3SS subtype (Figure 4.2). Neither SpaO nor FliM-FliN are 
pulled down by the APAR from a second pathogenic T3SS found in S. 
typhimurium (SPI-2 SsaK).
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Figure 4.1: SPOA domains in the S. typhimurium genome. Prospective 
annotation of the six SPOA domains in the S. typhimurium genome based on the 
SpaO structures presented here and those of its injectisome and flagellar 
homologues. Note that the prediction of an internal translation start site at M217 
in SsaQ is based on the work of Ghosh and colleagues (141). FliM and FliN are 
expressed from tandem open reading frames in the same operon.
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Figure 4.2: SPOA-APAR interactions are T3SS subtype specific. Coomassie-
stained gels showing the input and imidazole elution for APAR-SPOA co-affinity 
purification experiments. Red asterisks indicate the cognate SPOA1-SPOA2 
band(s). Abbreviations: T4lyso: T4 lysozyme; O1,2: SpaO(140-297); O2: 
SpaO(232-297); M: FliM(245-320); N: FliN (1-137); n: co-purifying amino-terminal 
FliN degradation product.
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4.2 Structural basis for the interaction of FliM(SPOA) with FliN(SPOA)
I hypothesized that divergence of the SPOA1-SPOA2-APAR assembly 
architecture contributes to proper component segregation among T3SS 
subtypes, and sought to structurally characterize the flagellar SPOA-APAR 
interactions. While complexes of the FliM SPOA and FliN were stable, they were 
resistant to crystallization. Interestingly, FliM and FliN can be fused and still 
support flagellin secretion (Figure 4.3) and some swarming motility (189). In a 
sense, such FliM-FliN fusions are analogous to SpaO(ValGTT203), in that a single 
polypeptide contains both SPOA domains and no free SPOA2 is produced.
A construct containing the SPOA of FliM (residues 245-334) fused to 
FliN(5-137) was expressed in E. coli and purified by anion exchange and size 
exclusion chromatography (Figure 4.3). This construct readily crystallized, and 
SeMet-doped material gave rise to crystals with diffraction characteristics 
superior to native protein. The FliM(245-334)::FliN(5-137) structure was solved 
by SeMet SAD and refined to 2.56 Å using the SeMet data set (Figure 4.4 and 
Table 4.1).
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Figure 4.3: Expression, purification, and function of FliM-FliN fusion 
protein. (A) FliM-FliN fusion is compatible with flagellar secretory function. 
Coomassie-stained PAGE of culture supernatants from S. typhimurium with the 
indicated genotype (WT, wild-type; ΔMN, deletion of fliM and fliN; M::N, FliM-
FliN(5-137) fusion). Flagellar specific secretory products (lost in the fliM/fliN 
deletion background) are present in the FliM-FliN fusion strain (blue asterisks 
highlight FliC and FlgL). The FliM::FliN fusion brings FliN residue 5 in frame with 
full-length FliM; both Met1 and Met4 of FliN are deleted to prevent spurious 
translation of free FliN. (B-D) Purification of FliM(245-334)::FliN(5-137). NiNTA 
purified protein (“E”) was cut with 3C and subjected to anion exchange 
chromatography (B). The main peaks (i) were then further purified by size 
exclusion chromatography (C), peak (ii). (D) Coomassie-stained gel  of E, i, ii.
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Figure 4.4: Diffraction analysis of FliM(245-334)::FliN(5-137). (A) Crystals and 
(B) diffraction image of the FliM-FliN fusion protein (SeMet incorporated). (C) 
Stereoimage of a selected region of the 2Fo-Fc electron density map for the 2.56 
Å FliM(245-334, cyan)::FliN(5-137, green) structure. The map is contoured to 1σ.  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Data       
Collection
Space group P212121
Cell: a, b, c (Å) 75.15, 81.50, 89.96
Cell: α, β, γ (°) 90, 90, 90




Completeness (%) 100 (100)








B factors: Protein 68.30
B factors: Ligand/ion 73.40
B factors: Water 64.50
Geometry (r.m.s.d.)
Bond lengths (Å) 0.010
Bond angles (°) 1.31
[Φ,Ψ] Favored (%) 92
[Φ,Ψ] Allowed (%) 99.1
[Φ,Ψ] Outliers (%) 0.9
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In the FliM(245-334)::FliN(5-137) structure, only the SPOA domains were clearly 
structured (FliM: 258-330; FliN: 53-137). Architecturally, the FliM(SPOA1)-
FliN(SPOA2) interaction is similar to that of SpaO (Figure 4.5, 2.28 Å RMSD), 
with the exception of additional helices present at the carboxy terminus of each 
SPOA, as observed in FliN homodimers from Thermotoga maritima (139). 
Additional weak density was observed in contact with the surface of the SPOA-
SPOA structure that was strong enough in segments to be modeled as peptide. I 
hypothesize that this additional density corresponds to the ~50 residues at the 
amino terminus of FliN linking the two SPOA domains in this artificial fusion. 
While it is tempting to speculate that these contacts are physiologically 
significant, it has not yet been determined that they are anything other than an 
artifact of the fusion strategy and/or crystal packing and thus will not be 
discussed further here.
Figure 4.5: Structure of FliM(SPOA)-FliN(SPOA). (A) Asymmetric unit of the 
FliM(245-334, cyan)::FliN(5-137, green) crystal. Noncontiguous modeled peptide 
fragments are shown in gray. (B) Superposition of the two constituents of the 
asymmetric unit (0.56 Å r.m.s.d) reveals a stereotypical SPOA-SPOA interaction. 
(C) The topology diagram is consistent with a bona fide SPOA fold for both FliM 
and FliN. (D) Superposition of apo-SpaO SPOA1-SPOA2 (light blue and green, 
respectively) with apo-FliM::FliN (dark blue and green, respectively; 2.28 Å 
r.m.s.d.).
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Figure 4.5: Structure of FliM(SPOA)-FliN(SPOA).
The FliM(245-334)::FliN(5-137) fusion protein eluted from size exclusion 
chromatography as a much larger particle than would be expected for a 
monomer of its size (Figure 4.3). Dynamic light scattering analysis of gel filtration 
purified protein suggested the presence of a relatively monodispersed entity with 
a 36 Å ± 1 Å hydrodynamic radius and a predicted molecular mass of 65 kDa ± 3 
 106
kDa (Figure 4.6). Interestingly, the crystallographic asymmetric unit contained a 
dimer of fusion proteins with a diameter of 50-55 Å (mass: 50 kDa; Figure 4.5). 
Previous studies have noted the ability of FliN to tetramerize into a similar 
doughnut-like annulus (139) and have speculatively assigned this structure to the 
distal cytoplasmic aspect of the C-ring cryo-EM density, because of its quasi-
toroid appearance. I posit that while neither the FliN homotetramer nor FliM-FliN 
heterotetramers (FliM2-FliN2 or FliM-FliN3) can be definitively ascribed to the 
density in question using the data available, the FliM-FliN heterotetramers should 
be considered alongside the FliN homotetramer as a candidate for the 
composition of this structure.
Figure 4.6: Solution behavior of FliM(245-334)::FliN(5-137). The data for 40 
µM protein is shown in the autocorrelation and regularization graphs. In the 
autocorrelation graph, the raw data is shown in blue and the regularization fit is 
shown in violet.  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4.3 Structure of the FliM(SPOA)-FliN(SPOA)-FliH(APAR) complex
The similarity of the SpaO and FliM/FliN SPOA1-SPOA2 structures is consistent 
with a model for SPOA1-SPOA2 interactions being generalizable across T3SS 
subtypes. Is the mechanism of APAR binding also structurally similar across 
T3SS subtypes? 
To elucidate the mechanism of FliH-specific assembly with FliM-FliN, I 
sought to co-crystalize the SPOAs of FliM and FliN in complex with the FliH 
APAR as a T4 lysozyme fusion. FliM(245-320), FliN(1-137), and FliH(1-43)::T4 
lysozyme formed a stable complex over size exclusion chromatography (Figure 
4.7); however this complex was resistant to crystallization.  As one would predict 
from the FliM-FliN fusion protein’s function in vivo, FliM(245-334)::FliN(5-137) 
was able to bind the FliH APAR (residues 1-43) fused to lysozyme (Figure 4.7). 
The APAR construct fused to lysozyme was further truncated to residues 1-18, 
which still formed a complex with FliM(245-334)::FliN(5-137) (Figure 4.8). This 
complex crystallized, its structure was solved to 2.30 Å resolution by molecular 
replacement using the FliM(245-334)::FliN(5-137) model and T4 lysozyme 
(Figure 4.9, Table 4.2)
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Figure 4.7: FliM-FliN-FliH complexes. (A) Separation of excess FliH(1-43)::T4 
lysozyme fusion from the FliM-FliN-FliH::T4 lysozyme complex by size exclusion 
chromatography. (B) Co-affinity purification of FliM(245-334)::FliN(5-137) with 
hexahistidine-tagged FliH(1-43)::T4 lysozyme over NiNTA resin. Gels in (A) and 
(B) are coomassie-stained.
Figure 4.8: Expression and purification of FliM(245-334)::FliN(5-137) + 
FliH(1-18)::T4 lysozyme. FliH(1-18)::T4 lysozyme fusion (H::T4) was purified 
under denaturing conditions (E), refolded, and affinity tags were removed with 3C 
protease. Cleaved protein was further purified by cation-exchange 
chromatography (A), mixed with FliM(245-334)::FliN(5-137) (M::N), and excess 
H::T4 (iii) was separated from the complex (ii) by gel filtration chromatography 
(B). Inset, Coomassie-stained gel of E and the main chromatography peaks.  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Figure 4.9: Diffraction analysis of FliM(245-334)::FliN(5-137) + 
FliH(1-18)::T4lysozyme. (A) Representative crystals and (B) diffraction pattern 
for the FliM(245-334)::FliN(5-137) + FliH(1-18)::T4 lysozyme complex. (C) 
Stereoimage of the 2Fo-Fc electron density map for the 2.30 Å FliM(245-334, 
cyan)::FliN(5-137, green) + FliH(1-18)::T4 lysozyme (gray) structure. The map is 
contoured to 1σ and highlights the FliH W7 binding region.
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Data       
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Space group P212121
Cell: a, b, c (Å) 43.21, 76.37, 119.4
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B factors: Ligand/ion  
B factors: Water 65.00
Geometry (r.m.s.d.)
Bond lengths (Å) 0.009
Bond angles (°) 1.15
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[Φ,Ψ] Allowed (%) 99.1
[Φ,Ψ] Outliers (%) 0.9
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As with its injectisome counterparts, the FliM-FliN SPOA1-SPOA2 did not 
undergo large conformational changes upon APAR binding (Figure 4.10B, 1.11 Å 
r.m.s.d.); however, the binding mode for the FliH APAR is radically different. In 
contrast to the OrgB pseudo-lariat, the FliH APAR adopts a near-linear 
conformation along the “top” of FliM-FliN (Figure 4.10C). As observed in the 
SpaO-OrgB assembly, the FliH APAR makes extensive contact with both SPOA1 
and SPOA2 (Figure 4.10C), supporting the observation that the FliH APAR 
interacts more strongly with the FliM-FliN heterodimer than the FliN homodimer 
(Figure 4.2). 
The FliM-FliN-FliH assembly is characterized by the burial of several 
highly conserved hydrophobic FliH side-chains. Two tryptophan side-chains form 
an aromatic “clamp,” which binds hydrophobic pockets on opposite faces of the 
FliN thumb (Figure 4.10D). Alanine scanning mutagenesis of the FliH amino 
terminus had previously identified these tryptophans as critical for flagellar 
function (133), and they are highly conserved (Figure 4.10). Similarly, the bulky 
side-chain of FliH Leu15 fills a hydrophobic pocket on the thumb of FliM (Figure 
4.11). The binding interfaces for these three residues are formed by both FliM 
and FliN and are highly conserved across species (Figure 4.11E). This structure 
presents a conserved model for FliH-FliM-FliN interaction, which is distinct from 
that of SpaO-OrgB.
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Figure 4.10: Structure of the FliM(SPOA)-FliN(SPOA)-FliH(APAR) complex. 
(A) The crystallographic asymmetric unit for FliM(245-334, cyan)::FliN(5-137, 
green) + FliH(1-18)::T4 lysozyme (gray). (B) Superposition of apo- (cyan/green) 
and APAR-bound (blue/dark green) FliM::FliN (1.11 Å r.m.s.d.). (C) Ribbon 
diagram (left) and surface representation (right) of the FliM-FliN-FliH structure. T4 
lysozyme has been omitted. N and C indicate the amino- and carboxy-termini of 
the FliH APAR, respectively. (D) A zoomed view of the FliH aromatic clamp, with 
the side-chain atoms of FliH W7 and W10 represented as spheres. (E) Excerpted 
M-COFFEE alignment of FliH with its homologues from S. flexneri, Y. 
enterocolica, and P. aeruginosa. Highly conserved residues of interest are noted 
(S. typhimurium numbering shown). 
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Figure 4.10: Structure of the FliM(SPOA)-FliN(SPOA)-FliH(APAR) complex.
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Figure 4.11: Surface characteristics of the FliH(APAR) binding site. The 
binding pockets for FliH W7, W10, and L15 on FliM-FliN are shown as surface 
renderings. On the left, the surface is color coded by residue conservation across 
S. typhimurium, S. flexneri, Y. enterocolica, and P. aeruginosa. Red indicates 
100% identity. Orange, yellow, and white indicate high, medium, and low 
conservation by M-COFFEE multiple sequence alignment. In the middle, the 
same surface is shown but color-coded by chain: FliM is cyan, FliN is light green. 




THE SpaO AMINO-TERMINAL DOMAIN
The preceding chapters have presented structures for SPOA1-SPOA2 and 
SPOA2-SPOA2 complexes. In the case of the former, this architecture is 
conserved from injectisomes to the flagellar apparatus and functions as a 
scaffold for the SctL/FliH APAR. What, though, is the function of the SPOA2 
homodimer? Similarly, my structural dissection of SpaO and its homologues has 
thus far neglected its 140 amino-terminal residues: what might be their structure 
and function? 
In Chapter 2, I presented data showing that free SPOA2 binds to full 
length SpaO and remains as a complex through purification (Figures 2.1 and 
2.2). Thus, I hypothesized that free SPOA2 might be able to interact with either 
the SPOA1-SPOA2 complex (residues 140-297) or with the SpaO NTD in 
isolation. To test the former possibility, SpaO(140-297) was mixed with 
SpaO(232-297) and passed over a size exclusion chromatography column. 
There was no shift in elution volume for either component, indicating a lack of 
complex formation (Figure 5.1A). 
The amino-terminal domain (NTD) of SpaO is necessary for T3SS, as its 
genomic deletion completely disrupts secretory function (Figure 5.1B). While 
T3SS function is fully complemented by SpaO(1-303) in this mutant, it is only 
partially complemented by the deleted domain (residues 1-140) (Figure 5.1B). 
While secretion of some substrates is clearly restored (orange asterisk in Figure 
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5.1B), secretion of other substrates is only partially restored (purple asterisks) or 
is not restored at all (green asterisk), suggesting that full SpaO NTD function 
requires covalent linkage to SPOA1-SPOA2. While biochemical analysis or 
(ideally) structure determination might shed light on the intriguing function of the 
NTD, such efforts have been impeded by its poor solubility. Inspired by my 
success at producing the OrgB and FliH APAR peptides as T4 lysozyme fusions, 
I fused SpaO(1-142) to lysozyme and found that the fusion protein could be 
solubly refolded (Figure 5.1C). In contrast to SPOA1-SPOA2, the SpaO NTD::T4 
lysozyme construct interacted with free SPOA2, as determined by co-affinity 
purification (Figure 5.1D).
Figure 5.1: The SpaO NTD interacts with SPOA2. (A) Mixing SpaO(140-297) 
with SpaO(232-297) does not result in a complex with a smaller elution volume 
on size exclusion chromatography. (B) Coomassie-stained SDS-PAGE of S. 
typhimurium culture supernatants grown under T3SS stimulating conditions. 
Abbreviations: FL, full length SpaO; ΔO, deletion of spaO; Δ1-140, deletion of 
spaO codons 1-140; 1-140, complementation with SpaO(1-140). SpaO was 
3xFLAG tagged at its amino terminus in each S. typhimurium strain (except ΔO) 
and complementation construct. Asterisks highlight bands of interest, as 
described in the text. (C) Size exclusion chromatography of refolded 
SpaO(1-142)::T4 lysozyme is consistent with a monodispersed sample. (D) Co-
affinity purification of SpaO(1-142)::T4 lysozyme with double hexahistidine 
tagged SpaO(SPOA2) is robust and substantially greater than background 
binding of SpaO(1-142)::T4 lysozyme to NiNTA resin in the absence of a 
hexahistidine-tagged binding partner.  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Figure 5.1: The SpaO NTD interacts with SPOA2.
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To confirm and expand on the finding that free SPOA2 interacts with the SpaO 
NTD and not SPOA1-SPOA2, these interactions (or lack thereof) were probed by 
isothermal titration calorimetry (Figure 5.2). Free SPOA2 bound to 
SpaO(1-142)::T4 lysozyme with a dissociation constant of 20.0 µM ± 0.22 µM at 
25°C. The binding isotherm was consistent with the NTD interacting with dimeric 
SPOA2, as the calculated binding stoichiometry was 1:1.05 (±0.02) when the 
SPOA2 concentration was input as the concentration of SPOA2 dimers. Binding 
was exothermic and completely enthalphy driven (∆H = -14500 ± 36 cal/mol; ∆S 
= -27.1 ± 0.1 cal/mol/deg). No specific interaction with free SPOA2 was detected 
for SpaO(140-297).
Given the interaction of SPOA2 homodimers with the SpaO NTD, I 
hypothesized that the NTD might be stably co-refolded with SPOA2.  Indeed, 
SpaO(1-140) could be refolded with SpaO(232-297) and the complex was stable 
over size exclusion chromatography (Figure 5.3). Thus far, the complex has 
resisted crystallization, but it is hoped that further screening and construct re-
engineering might yield diffraction quality crystals of this complex.
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Figure 5.2: Quantitative analysis of the SpaO NTD-SPOA2 interaction. 
Representative ITC data for the SpaO SPOA2 interacting with the SpaO NTD 
(left) and SPOA1-SPOA2 (right). The uncorrected power differential between the 
reference and sample cells is shown on top; the background subtracted heats 
are shown on the bottom. The concentration of SPOA2 dimers in solution was 
used to calculate the molar ratio.
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Figure 5.3: The SpaO NTD co-refolds with SPOA2. A SpaO (O) NTD construct 
can be purified under denaturing conditions and co-refolded with SPOA2 
(denaturing NiNTA elution shown, E). After refolding and filtration (RF Super.), 
soluble material was liberated from its affinity tags (12HIS) by 3C protease and 
soluble aggregate (uncleaved, i) separated from the NTD-SPOA2 complex (ii). 
Some excess free SPOA2 remained as a chromatographic shoulder (iii).
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CHAPTER 6: 
CONCLUSIONS AND FUTURE DIRECTIONS
6.1 SPOA domain structure
I have presented here a series of structures and supporting biochemical and cell 
biological data that yield critical mechanistic insights into T3SS sorting platform 
assembly across multiple species and secretion subtypes. The existence of 
heterotypic SPOA interactions provides a structural explanation for the previously 
reported 1:2 stoichiometry of full length protein to free SPOA2 in SpaO 
homologues (141). While two of these SPOA2 domains could be accounted for 
by a homodimer interacting with full length SpaO, the conformation of the third 
SPOA2 (located in the full length protein) was unclear. Previous reports had 
proposed the existence of an alternate autostabilizing conformation for the third 
SPOA2, wherein the fingers of the SPOA domain in the full length protein “snap 
back” against its own palm to bury the surfaces located at the dimerization 
interface in SPOA homodimers (141). We show here that this third SPOA2 can 
be stabilized by a SPOA1-SPOA2 interaction, and that the SPOA2 homodimer 
interacts with the SpaO NTD (Figure 6.1).
What might be the function of the SPOA2 homodimer-NTD interaction in 
SpaO and its SctQ-family homologues? Studies in Yersinia argue that the 
cryptically translated SPOA2 fragment is necessary for T3SS function (141) and 
formation of perimembranous SctQ-containing puncta (137). However, 
preliminary data and communications with others in the field indicate that this is 
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not the case in S. typhimurium. Perhaps the SPOA2 homodimer functions as a 
chaperone, stabilizing the SpaO NTD until it can interact with some components 
of the T3SS basal body or export gate. This would be consistent with the marked 
decrease in solubility of full length SpaO when the internal translation start site is 
mutated (Figures 2.1, 3.1), and might explain why the SPOA2 homodimer is 
unnecessary for T3SS function under the “forcing” conditions of high salt 
stimulation. Further biochemical analysis of the SctQ NTD and its binding 
partners is needed to address this question, and whether the SPOA2 homodimer 
is necessary for S. typhimurium T3SS function under physiologic conditions (i.e. 
infection) should be determined.
The ratio of FliM to FliN in situ is estimated to be 1:3 (188). In the context 
of our FliM-FliN structure, this suggests a model for FliM-FliN interaction similar 
to that of SpaO. FliM(SPOA1) would engage FliN(SPOA2) in a heterotypic 
SPOA-SPOA interaction, much like the interaction between SPOA1 and SPOA2 
in full length SpaO. Additional homodimeric FliN would interact with FliM-FliN in 
an as of yet undetermined fashion, analogous to the SpaO SPOA2 homodimer 
interaction with the SpaO NTD (Figure 6.1). However, several lines of evidence 
suggest that FliN homo-oligomers might not interact with the regions of FliM 
amino-terminal to its SPOA domain in a manner homologous to the SpaO NTD-
(SPOA2)2 interaction. First, the SpaO NTD and the pre-SPOA regions of FliM do 
not share noteworthy sequence homology, and portions of this region of FliM are 
known to interact with flagellar-specific proteins (e.g. FliG, CheY) involved in 
torque generation and flagellar rotation switching (145, 146). Second, FliN homo-
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oligomers may interact with the FliM(SPOA)-FliN region instead, as co-affinity 
purification of hexahistidine-tagged FliM(SPOA) with FliN results in a co-purifying 
stoichiometric excess of FliN that separates from 1:1 FliM-FliN on ion-exchange 
chromatography (not shown).  Moreover, reports of FliN tetramerization and 
FliM:FliN ratios between 1:3 and 1:4 suggest that more complicated higher order 
structures may be utilized by the flagellar apparatus (139).
Figure 6.1: Overview of domain interactions within SPOA-containing 
proteins.  (A) Schematic of the domain interactions for the SctQ family prior to 
this study. S indicates SPOA domains; N, the domains amino-terminal to the 
SPOA; ??, uncertain targets of interaction. (B) The model in (A) requires an 
autostablizing conformation of the SPOA domain, like the “snap back” model 
shown here. (C) Schematic of SpaO domain interactions described in this work. 
NTD, amino-terminal domain; 1, SPOA1; 2, SPOA2. (D) Schematic of FliM-FliN 
domain interactions, both hypothetical and demonstrated. MNTD indicates the 
regions of FliM amino-terminal to the SPOA; MS, FliM SPOA; NS, FliN SPOA. 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6.2 The SPOA-APAR interaction
The structures presented here suggest a partial model for the subtype-specific 
assembly of the T3SS sorting platforms: the SPOA1-SPOA2 module within a 
given T3SS subtype functions as an adaptor for the ATPase and its regulator 
through interaction with the APAR peptide (Figure 6.2). It should be noted that 
while previous investigations of the flagellar T3SS have focused on the 
interaction between FliH and FliN specifically (133), my structures and 
biochemical data show that the FliH APAR more strongly interacts with the FliM-
FliN complex than with FliN alone, suggesting that the FliM-FliN complex is the 
physiologically relevant binding partner for FliH.
It is intriguing that disruption of the SPOA-APAR interaction prevented 
membrane localization of the SpaO sorting platform. What might be the 
mechanism for sorting platform targeting? One might imagine four non-mutually 
exclusive scenarios in which the SPOA-APAR interaction promotes SpaO 
membrane localization (ii-iv are diagrammed in Figure 6.3): 
(i) InvC-OrgB has constitutive membrane localizing activity, and the SPOA-
APAR interaction simply facilitates the trafficking of SpaO as inert cargo.
(ii) At baseline, the APAR binds to a region of InvC or OrgB preventing InvC-
OrgB from localizing to the membrane (either by direct competition for a 
binding site or allosterically). SpaO binding of the APAR releases the 
inhibition, allowing membrane localization of the complex.
(iii) At baseline, the SpaO NTD is sequestered by interacting with SPOA1-
SPOA2. Binding to the APAR releases the NTD, allowing it to interact with 
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membrane lipid or injectisome-associated proteins, driving membrane 
targeting.
(iv) The SPOA-APAR assembly might function as a scaffold module, inducing 
proximity between sorting platform components whose interactions then 
drive membrane localization.
Figure 6.2: Segregation of homologous sorting platform components by 
subtype-specific SPOA-APAR interactions. Schematic illustration of the 
proposed role for the SPOA1-SPOA2-APAR assembly in organizing and 
localizing the T3SS sorting platforms in a subtype-specific fashion. IM indicates 
the inner membrane; ONTD, the SpaO amino-terminal domain(s); 1 and 2, SpaO 
SPOA1 and SPOA2; B, OrgB; H, FliH; MNTD, the FliM amino-terminal domains; M 
and N, the SPOA domains of FliM and FliN; Injectisome, the membrane integral 
components of the pathogenic T3SS; Flagellar BB, the flagellar basal body and 
associated integral membrane components.  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Figure 6.3: Hypothetical mechanisms of sorting platform targeting to the 
injectisome. Schematic representation of three hypothetical mechanisms for 
SPOA-APAR interaction-induced membrane localization of the sorting platform 
(ii, iii, and iv). Abbreviations are the same as in Figure 6.2, except MLD denotes 
membrane localization domain. X represents some hypothetical interacting 
protein or even a portion of the SpaO NTD. 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One might distinguish among these hypothetical mechanisms with a series of 
genetic experiments utilizing genomic encoded GFP fusions. For example, 
hypothesis (i) would predict that deletion of neither spaO nor the orgB APAR 
would affect GFP::InvC localization to perimembranous puncta. However, 
hypothesis (ii) would predict that deletion of spaO would impair GFP::InvC 
localization to the membrane, and that phenotype would be rescued by deletion 
of the orgB APAR. Both hypotheses (i) and (ii) would predict that 
GFP::SpaO(SPOA1-SPOA2) would localize to the membrane in an OrgB-
dependent fashion, but that GFP::SpaO(NTD) would show cytoplasmic 
localization. By contrast, hypothesis (iii) would predict that GFP::SpaO(NTD) 
would be membrane localized, regardless of invC or orgB genotype, and that 
GFP::SpaO(SPOA1-SPOA2) would be cytoplasmic. Lastly, hypothesis (iv) would 
predict that both GFP::SpaO(NTD) and GFP::SpaO(SPOA1-SPOA2) would be 
localized to the cytoplasm.
Hypothesis (iii) — that the SpaO NTD has membrane localizing activity 
and that this activity is sequestered prior to SPOA-APAR interaction — is 
particularly intriguing on several levels. First, early preliminary data suggests that 
GFP::SpaO(NTD) does localize to the membrane (not shown). Second, this 
hypothesis would imply a testable function for the NTD interaction with the inner 
membrane or some membrane associated T3SS component (discussed further 
in Section 6.3, below). Third, this hypothesis implies an interaction between the 
NTD and the SPOA1-SPOA2 module prior to APAR binding. Preliminary data do 
not demonstrate the existence of such an interaction when the modules are not 
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covalently linked (pull down experiments, not shown). However, in the context of 
the full length protein, these domains would be constrained by their covalent 
linkage, and so even low affinity, transient interactions between the domains 
might be functionally relevant. Of course, capturing full length SpaO in a crystal 
for diffraction analysis remains a priority for the field; however, solution NMR may 
offer some insight into whether these presently hypothetical interactions exist and 
are worth pursuing. For example, if the TROSY “fingerprint” for SpaO(140-297) 
(Figure 2.10) is altered in the context of the full length protein, it would suggest 
that the NTD makes contact with the SPOA1-SPOA2 module. In particular, one 
might imagine a case where the APAR-binding region shows signs of 
perturbation, consistent with some portion of the NTD docking in that site.
Regardless of the underlying mechanism, the finding that the SPOA-APAR 
interaction is necessary for T3SS function makes it an interesting target for the 
development of potential anti-virulence compounds. Unlike other potential anti-
virulence targets in the T3SS that have human homologues (e.g. the SctN 
ATPase), the SPOA fold appears to be unique to the T3SS, with no reported 
structures possessing this fold in other systems, raising the prospect that 
therapeutics targeting this interaction could have little off-target toxicity to the 
host. In particular, the high degree of sequence (and presumably structural) 
conservation among the flagellar SPOA-APAR pairs suggests that it might even 
be possible to target the flagellar apparatus with “broad spectrum” efficacy. 
The design of therapeutics targeting the SPOA-APAR interaction would 
not be without major challenges, though. While it is tempting to use the APAR 
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peptide structures themselves as models for the development of “APAR-
mimetics” that could compete with the endogenous peptide for SPOA-binding, 
the relatively low affinity (Kd=2.0 µM) of the interaction is not within the 
nanomolar range typically seen as attractive in a pharmacologic lead compound. 
Indeed, the APAR peptides in both the SPI-1 T3SS and flagellar apparatus bind 
large exposed protein surfaces, not the deep pockets that are most amenable to 
tight, “lock and key” fits of small molecules. 
Nonetheless, I have developed a Förster resonance energy transfer 
(FRET)-based assay for the high throughput screening of small molecule 
disruptors of the SPOA-APAR interaction. The architecture of the SPOA-APAR 
complexes (both flagellar and SPI-1) place APAR and SPOA domain termini 
within the Förster radius of the modified yellow fluorescent protein-cyan 
fluorescent protein pair, Venus-Cerulean (R0=52 Å, ref. (190); Figure 6.4C,D), 
suggesting that fusions to these fluorescent proteins at the indicated termini 
might generate a detectable FRET signal in vitro. Carboxy-terminal fusion of 
Venus to SpaO(115-297) is compatible with protein expression and soluble 
purification from E. coli. In the presence of the previously characterized 
OrgB(1-30)::Cerulean fusion, substantial FRET is observed (Figure 6.4A,B). 
Neither fusion protein exhibits FRET in the presence of the other fluorescent 
protein without the cognate interaction partner, ruling out nonspecific interactions 
between either SpaO or OrgB and the fluorescent proteins as a spurious cause 
of FRET (Figure 6.4B). 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Figure 6.4: A FRET-based assay for high throughput drug screening. (A) 
Fluorescence emission scans of 100 µM each Cerulean and Venus (blue) or 
OrgB(1-30)::Cerulean and SpaO(115-297)::Venus (orange). Excitation 
wavelength fixed at 435 nm. Single asterisk highlights donor quenching, and 
double asterisk highlights acceptor stimulated emission. (B) Relative FRET 
efficiencies, scaled to Cerulean + Venus = 0. Abbreviations: C, Cerulean; V, 
Venus; APAR::C, OrgB(1-30)::Cerulean; SpaO::V, SpaO(115-297)::Venus; C5V, 
Cerulean and Venus connected by a 5 amino acid linker. Each mixture contained 
100 µM of each fluor. Values are the mean of five technical replicates; error bars 
are +/- the standard deviation. (C, D) Structural basis for the design of 
fluorescent protein fusion FRET probes for the SPI-1 (C) and flagellar (D) SPOA-
APAR interaction. 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6.3 Higher order interactions in the T3SS sorting platform
A number of questions remain regarding the higher order architecture of the 
sorting platform in situ. I hypothesize that the puncta formed by SpaO in vivo 
represent the high-molecular weight sorting platforms described by Galán and 
colleagues (129).  Armitage and colleagues have quantified the stoichiometry 
and dynamics of these puncta in Yersinia, showing them to possess ~22 copies 
of YscQ (SpaO homologue) per punctum and to be in dynamic exchange with the 
cytoplasm (137). In contrast, Liu and colleagues’ recent tomographic 
reconstruction of Shigella injectisomes revealed the presence of only six SpaO 
homologue-dependent pods of density beneath the injectisome, and their 
localization was OrgB homologue-independent (128).  Taken together with my 
findings, these results suggest that there may be two subpopulations of SpaO in 
vivo: one stably associated with the injectisome, and a second dynamic 
population in exchange with the cytoplasm, requiring the SPOA-APAR interaction 
to form high molecular weight, perimembranous sorting platforms. Recent 
analyses of FliI ATPase dynamics by Minamino and colleagues suggest a similar 
two population model, which they hypothesize functions to deliver secretion 
substrates to the assembling flagella (136).
Integrating SpaO structures into such models of sorting platform assembly 
function will require further exploration of the interactions between constituents of 
the large complex reported by Galán and colleagues (129). For example, the 
structure of the sorting platform component OrgA remains to be determined, and 
its role in platform assembly is similarly opaque. Its apparent insolubility and 
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previous reports of self association in yeast two hybrid studies (182) suggest that 
it may play a role in high molecular weight oligomerization of the sorting platform. 
While OrgA lacks a clear flagellar homologue, the flagellar protein FliG (which 
itself lacks a clear injectisome homologue) self associates to organize C-ring 
assembly (191), and it is temping to speculate that these non-homologous 
proteins might be functional analogues. 
Similarly, the biochemical basis for sorting platform association with the 
basal body (e.g. SctD), the export apparatus (SctV), and/or their associated 
regulators (e.g. SctP, SctW, SctO, SctU) remains to be determined and may offer 
further insights into the mechanism of sorting platform localization to the 
injectisome superstructure. For example, previous work in Shigella identified a 
peptide from SctQ that interacts with the cytoplasmic domain of the basal body 
protein SctD (47). My structures would place this peptide in the “fingers” region of 
SPOA1, a plausible site for an interaction interface. However, I have been unable 
to reproduce an interaction between SpaO and PrgH (SctD) in vitro (not shown), 
and others have questioned the physiologic relevance of this interaction (48).
Lastly, the implications of sorting platform assembly for substrate 
recruitment, dechaperoning, and secretion remain unclear, and will require 
further studies of interactions between substrate-chaperone pairs and the sorting 
platform, the ATPase, and the export gate. Indeed, analysis of these complexes 
may even offer insight into the recruitment of the sorting platform to the 
injectisome, as interactions with substrate-chaperone pairs have been 
hypothesized to bridge the sorting platform and the injectisome basal body (48). 
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However, with few exceptions (125), such complexes of substrates, chaperones, 
and components of the sorting platform or export apparatus have not proven 
sufficiently stable for rigorous structural interrogation. 
Ideally, micro-level insights from structural characterization of the 
aforementioned complexes will be paralleled with improvements in the electron 
microscopic (or, potentially, X-ray crystallographic) maps of the holo-injectisome 
and flagellar apparatus, allowing the incorporation of precise structural details 
into larger scale structural models of T3SS structure and function.
6.4 Technical considerations
The use of T4 lysozyme as a peptide stabilizing agent and crystallization 
chaperone merits brief technical consideration.  For both the SpaO-OrgB and 
FliM-FliN-FliH structures, T4 lysozyme fusions were used to solubilize peptides 
with considerable hydrophobic character and also supplied additional 
crystallogenic packing interfaces.  While T4 lysozyme fusions have received 
attention for their ability to facilitate the crystallization of membrane proteins, their 
applicability as general crystallization chaperones is less well studied.  Other 
large protein fusions have been used to facilitate the crystallization of globular 
proteins (183), and I propose that T4 lysozyme might be similarly useful. 
However, I did note that the intrinsic flexibility between the amino- and carboxy-
terminal lobes of T4 lysozyme resulted in substantially less order in the amino-
terminal lobe and model building for this region was challenging (Figure 6.5). 
Kobilka and colleagues also noted this phenomenon in their G-protein coupled 
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receptor::T4 lysozyme structures and have engineered T4 lysozyme variants to 
overcome it (192).  These re-engineered crystallization chaperones may prove 
useful to the crystallization of challenging globular proteins or protein-peptide 
interactions.
Figure 6.5: Disorder of the T4 lysozyme amino-terminal lobe complicates 
model building. (A) Model of one T4 lysozyme molecule from the SpaO-OrgB 
crystallographic asymmetric unit color coded by increasing (purple to red) B-
factor.  The amino- and carboxy-terminal lobes are indicated as “NT” and “CT,” 
respectively.  Asterisk indicates the substrate binding pocket.  (B) Comparison of 
the T4 lysozyme molecules from SpaO-OrgB (blue, purple) and FliN-FliM-FliH 
(pink) aligned globally.  Note the greater divergence of the amino-terminal lobe 





Sequence alignments were performed using Clustal Omega (178) or M-COFFEE 
(193). Secondary structure and disorder predictions were performed using the 
PSIPRED server (194). Coiled coil prediction was preformed using the COILS 
server (195).
7.2 Molecular biology and general microbiology
Polymerase chain reaction (PCR) was performed using OneTaq (New England 
Biolabs), Phusion (New England Biolabs), or PfuTurbo (Agilent) as per 
manufacturer guidelines with oligonucleotides purchased from Integrated DNA 
Technologies. All mutations or gene fusions were created by overlap extension 
PCR. Gene sequences from S. typhimurium were PCR amplified from the T3SS-
competent strains SB300 (wild-type; gift of J. Galán) or SB1741 (3xFLAG::SpaO, 
silent SpaO L79CTG to L79CTA variant; gift of J. Galán) (129). The T4 lysozyme 
(C54T, C97A) sequence was obtained from Addgene plasmid 18111. An 
additional mutation (D20N) in T4 lysozyme was made to decrease toxicity in E. 
coli (196), and the terminal three residues were mutated to alanines to decrease 
conformational entropy. 
Plasmid DNA was purified using silica spin columns (Epoch Life Sciences) 
and the manufacturer recommended buffers. Standard molecular biology 
 136
protocols were followed to clone sequences of interest into modified pCDFduet or 
pETduet vectors for expression in E. coli or pBAD for expression in S. 
typhimurium. Restriction enzymes and Quick Ligase (New England Biolabs) were 
used as per manufacturer specifications. E. coli were rendered chemically 
competent for transformation with DNA by growing cells to an OD600 of 0.3 and 
washing cells 4 times with 10 mM tris.Cl pH=7.0, 60 mM CaCl2 in 15% glycerol, 
85% water at 4°C and snap freezing cells in liquid nitrogen. Cells were thawed 
and incubated with DNA for 0.5 h on ice, heat shocked at 42°C for 60 s, 
recovered on ice for 2-5 minutes, and then grown in LB (formulation below) for 1 
h at 37°C prior to plating on LB agar with antibiotic selection.
LB broth (Miller formulation: 1% w/v tryptone, 0.5% w/v yeast extract, 1% 
w/v NaCl; Boston BioProducts) or LB agar (Lenox formulation: 1% w/v tryptone, 
0.5% w/v yeast extract, 0.5% w/v NaCl 1.5% w/v agar; Boston BioProducts) were 
used to culture bacteria unless otherwise specified. Antibiotics were used a the 
following concentrations: ampicillin, 100 µg/mL; streptomycin, 10 0µg/mL; 
kanamycin, 50µg/mL; tetracycline, 10 µg/mL.
S. typhimurium genomic mutants were produced using homologous 
recombination from SacB-expressing suicide plasmids (36). SM10λpir E. coli 
were used to carry suicide plasmids and deliver them to S. typhimurium by 
conjugation. Plasmid carrying SM10λpir (tetracycline resistant) and target 
Salmonella (streptomycin resistant) were grown overnight on LB agar plates, 
resuspended in LB broth, and pelleted by centrifugation for 5 minutes at 2300 g. 
The E. coli and Salmonella were resuspended together in 50-75 µL LB broth, 
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spotted to antibiotic-free LB agar plates, incubated at 37°C overnight, and spread 
on LB agar containing streptomycin and tetracycline. Exconjugates were 
restreaked on the same media. Individual colonies were picked and grown for 2 h 
in 1 mL LB with streptomycin and tetracycline, diluted 100-fold into a fresh 1 mL 
LB containing only streptomycin, grown for 2 h, and 1-10 µL were plated to L-
agar plates (1% w/v tryptone, 0.5% w/v yeast extract, 0.05% w/v NaCl, 1.5% 
agar) supplemented with 10% w/v sucrose and grown overnight at 30°C. Double 
recombinants were confirmed by PCR and tetracycline sensitivity. All spaO and 
orgB mutants were prepared on the SB1741 background. fliM and fliN mutants 
were prepared on the SB300 background.
S. typhimurium were rendered electrocompetent for transformation with 
DNA by growing cells to an OD600 of 0.3 and then washing 4 times with 10% 
glycerol at 4°C. Cells were incubated with salt-free DNA for 5 minutes before 
electroporation in 0.2 cm cuvettes with a Bio-Rad MicroPulser using the 
preprogrammed settings for gram-negative bacteria. Cells were recovered at 
37°C for 1 h prior to plating on LB agar with selective antibiotics.
Bacterial strains carrying plasmids (Table 7.1) or genomic modifications 
(Table 7.2) were stored by diluting an aliquot of overnight culture in LB 1:1 with a 
solution of 65% glycerol, 20 mM tris.Cl pH=8.0, 100 mM MgCl2 and frozen at 
-80°C. 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Table 7.1: Plasmids used in this study. Listed in order of appearance in the 
figures.
Plasmid ID E. coli Strain Description
1366 BL21DE3Gold 12HIS(3C)::SpaO(1-303) in Stebbins modified pCDF-Duet
7000 BL21DE3Gold 12HIS(3C)::SpaO(1-303, Val203GTT) in Stebbins modified 
pCDF-Duet
3013 BL21DE3Gold 12HIS(3C)::SpaO(1-303, Val203GTT) in Stebbins modified 
pCDF-Duet position 1. Position 2 contains SpaO(222-303).
3483 BL21DE3Gold 12HIS(3C)::SpaO(232-297) in Stebbins modified pCDF-Duet
3804 BL21DE3Gold 12HIS(3C)::SpaO(145-213) in Stebbins modified pCDF-Duet
3702 BL21DE3Gold 12HIS(3C)::SpaO(140-297, Val203GTT) in Stebbins modified 
pCDF-Duet
5860 BL21DE3Gold 3xFLAG::SpaO(1-219) in pBAD
6044 BL21DE3Gold 3xFLAG::SpaO(1-303) in pBAD
6046 BL21DE3Gold 3xFLAG::SpaO(1-303, stop after codon 140) in pBAD
5862 BL21DE3Gold 3xFLAG::SpaO(140-303) in pBAD
5213 BL21DE3Gold 3xFLAG::SpaO(204-303) in pBAD
5977 SM10λpir Suicide plasmid for spaO(∆1-202)
5973 SM10λpir Suicide plasmid for spaO(∆1-139)
5976 SM10λpir Suicide plasmid for spaO(Stop after codon 140)
5983 SM10λpir Suicide plasmid for spaO(double stop after codon 219)
5858 BL21DE3Gold InvC (untagged) in modified pET-Duet
5412 BL21DE3Gold 12HIS(3C)::SpaO(1-303) in Stebbins modified pCDF-Duet 
position 1. OrgB is in position 2.
3796 BL21DE3Gold 12HIS(3C)::SpaO(140-297, Val203GTT) in Stebbins modified 
pCDF-Duet position 1. OrgB is in position 2.
1658 BL21DE3Gold 12HIS(3C)::SpaO(1-303) in Stebbins modified pCDF-Duet 
position 1. OrgA is in position 2.
1835 BL21DE3Gold 12HIS(3C)::InvC in modified pET-Duet position 1. OrgB is in 
position 2.
1917 BL21DE3Gold SpaO(1-303) (untagged) in modified pCDF-Duet position 1, 
SpaO(203-303) in position 2.
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Table 7.1: Plasmids used in this study (continued).
Plasmid ID E. coli Strain Description
1930 BL21DE3Gold OrgA (untagged) in modified pCOLA-Duet position 1, 
SpaO(203-303) in position 2.
3006 BL21DE3Gold 12HIS(3C)::OrgA in Stebbins lab modified pCDF-Duet position 
1, SpaO(203-303) in position 2.
3599 BL21DE3Gold 12HIS(3C)::InvC in modified pET-Duet position 1. 
OrgB(31-226) is in position 2.
3474 BL21DE3Gold 12HIS(3C)::Thioredoxin(3C)::OrgB(2-30) in Stebbins modified 
pCDF-Duet
5180 BL21DE3Gold OrgB(1-30)::T4 lysozyme::6HIS in modified pCDF-Duet
3848 BL21DE3Gold 12HIS(3C)::OrgB(1-30)::T4 lysozyme in Stebbins modified 
pCDF-Duet
5631 BL21DE3Gold 12HIS(3C)::OrgB(1-30)::Cerulean in Stebbins modified pCDF-
Duet
3648 BL21DE3Gold 12HIS(3C)::OrgB(1-70) in Stebbins modified pCDF-Duet
5873 BL21DE3Gold 12HIS(3C)::SpaO(1-303) in Stebbins modified pCDF-Duet 
position 1. OrgB (I17D, L18D, I19D) is in position 2.
5868 BL21DE3Gold 12HIS(3C)::InvC in modified pET-Duet position 1. OrgB (I17D, 
L18D, I19D) is in position 2.
5946 SM10λpir Suicide plasmid for orgB(I17D, L18D, I19D)
5392 SM10λpir Suicide plasmid for EGFP::3xFLAG::spaO
5102 BL21DE3Gold 12HIS(3C)::InvA(316-686) in Stebbins modified pCDF-Duet
5152 BL21DE3Gold FliH(1-43)::T4 lysozyme::6HIS
5178 BL21DE3Gold SsaK(1-32)::T4 lysozyme::6HIS
3987 BL21DE3Gold 12HIS(3C)::FliM(245-320) in Stebbins modified pCDF-Duet 
position 1. FliN(1-137) is in position 2.
5968 BL21DE3Gold 12HIS(3C)::FliN(1-137) in Stebbins modified pCDF-Duet
5032 SM10λpir Suicide plasmid for ∆fliMN
5962 SM10λpir Suicide plasmid for fliM::fliN(5-137)
5100 BL21DE3Gold 12HIS(3C)::FliM(245-334)::FliN(5-137) in Stebbins modified 
pCDF-Duet
3879 BL21DE3Gold 12HIS(3C)::FliH(1-43)::T4 lysozyme in Stebbins modified 
pCDF-Duet
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Table 7.1: Plasmids used in this study (continued).
Plasmid ID E. coli Strain Description
5449 BL21DE3Gold 12HIS(3C)::FliH(1-18)::T4 lysozyme in Stebbins modified 
pCDF-Duet
4086 BL21DE3Gold 12HIS(3C)::SpaO(1-142)::T4 lysozyme in Stebbins modified 
pCDF-Duet
3675 BL21DE3Gold 12HIS(3C)::SpaO(1-140) in Stebbins modified pCDF-Duet
5671 BL21DE3Gold 12HIS(3C)::SpaO(115-297)::Venus in Stebbins modified pCDF-
Duet
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Table 7.2: S. typhimurium strains used in this study. Listed in order of 
appearance in the figures.
Strain ID Description
SB300 Wild-type. Gift of J. Gálan.
SB1741 3xFLAG::spaO. Gift of J. Gálan.
SB2130 ∆spaO. Gift of J. Gálan.
5161 3xFLAG::spaO(∆1-202)
6011 5161 carrying plasmid 5860
6033 SB2130 carrying plasmid 5860
6008 3xFLAG::spaO(double stop after codon 219)
5995 3xFLAG::spaO(∆1-139)
5999 3xFLAG::spaO(stop after codon 140)
6036 SB2130 carrying plasmid 5213
6035 SB2130 carrying plasmid 5862
6054 SB2130 carrying plasmid 6044
6056 SB2130 carrying plasmid 6046
SB2136 3xFLAG::spaO, ∆orgB. Gift of J. Gálan.
5683 3xFLAG::spaO, orgB(I17D, L18D, I19D)
5965 EGFP::3xFLAG::spaO
5958 EGFP::3xFLAG::spaO, ∆orgB
5925 EGFP::3xFLAG::spaO, orgB(I17D, L18D, I19D)
5057 ∆fliMN
5993 fliM::fliN(5-137)
6061 5995 carrying plasmid 6044
6062 5995 carrying plasmid 6046
 142
7.3 Protein expression and purification 
Constructs were transformed into BL21(DE3)Gold E. coli for heterologous 
expression and protein expression induced mostly as described (197). 
Specifically, bacteria were grown to an OD600 of 0.5-0.6 at 37°C in LB medium, 
the cultures were cooled to 18°C, induced with 250 µM IPTG, and grown 
overnight at 18°C. Selenomethionine (SeMet) substituted protein was produced 
in the methionine auxotrophic E. coli B834(DE3) grown in methionine-free media 
supplemented with SeMet (197). Uniformly labeled 15N/13C- or 2H/15N/13C- protein 
samples were produced by overexpression in isotopically enriched minimal 
media. Deuterium oxide, 15N-ammonium chloride, and 13C-glucose were obtained 
from Cambridge Isotope Labs.
After induction overnight at 18°C, cells were harvested by centrifugation 
and resuspended in lysis buffer (200 mM NaCl, 20 mM Tris(hydroxymethyl)-
aminomethane (tris).Cl pH=8.0, 5% v/v glycerol, 3 mM imidazole.Cl pH=8.0, 5 
mM MgCl2, 5 mM 2-mercaptoethanol, 1 mM PMSF, and 0.1 mg/mL DNaseI). 
Cells were lysed by 1-2 passes through a mechanical homogenizer (Avestin C5) 
at 4°C.
 Proteins were purified from E. coli cell lysates under native or denaturing 
conditions (as indicated for each downstream application below) and affinity 
purified on NiNTA agarose resin (Qiagen). For purification under native 
conditions, all steps were performed at 4°C. Lysate was clarified by centrifugation 
for 0.5 h at 30,000 g and loaded onto NiNTA resin by gravity flow. The column 
was washed with 5-10 volumes of wash buffer (200 mM NaCl, 20 mM tris.Cl 
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pH=8.0, 5%v/v glycerol, 30 mM imidazole.Cl pH=8.0) and then eluted in elution 
buffer (200 mM NaCl, 20 mM tris.Cl pH=8.0, 5%v/v glycerol, 360 mM 
imidazole.Cl pH=8.0). The elution was supplemented with 1 mM EDTA and 
dialyzed overnight against 200 mM NaCl, 20 mM tris.Cl pH=8.0, 1 mM 
dithiothreitol. Affinity tags were removed by cleavage with HRV 3C protease.
For purification under denaturing conditions, guanidinium chloride was 
added to the lysate to a final concentration of 6 M. The post extraction lystate 
was clarified by centrifugation at 30,000 g for 0.25 h at 4°C and loaded onto 
NiNTA resin in batch at 25°C. Still at 25°C, the resin was washed with denaturing 
wash buffer (8 M urea, 500 mM NaCl, 20 mM tris.Cl pH=8.0, 30 mM imidazole.Cl 
pH=8.0) and eluted in denaturing elution buffer (8 M urea, 200 mM NaCl, 20 mM 
tris.Cl pH=8.0, 360 mM imidazole.Cl pH=8.0). Urea containing solutions were 
stabilized by the addition of 75 mM ammonium sulfate. The elution was 
supplemented with 5 mM EDTA and 5 mM DTT and protein refolded by dialysis 
against 200 mM NaCl, 20 mM tris.Cl pH=8.0, 1 mM DTT (3-4 changes, dialysis 
time of 24 h total, 4°C). For T4 lysozyme fusions, 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES).Na pH=7.0 was substituted for tris.Cl 
pH=8.0. Insoluble material was removed by centrifugation or filtration and affinity 
tags were removed by cleavage with HRV 3C protease.
Affinity purified proteins were further purified by ion exchange 
chromatography using an AKTA FPLC and the following columns (GE 
Healthcare): T4 lysozyme fusions were purified by cation exchange on a 
SourceS column; all other constructs were purified by anion exchange on a 
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SourceQ column. For cation exchange chromatography, proteins were loaded in 
batch in 10 mM HEPES.Na pH=7.0, 50-100 mM NaCl and eluted by a NaCl 
gradient (from 0 to 1000 mM) in the same buffer.  For anion exchange, proteins 
were loaded in batch in 20 mM tris.Cl pH=8.0, 50-100 mM NaCl and eluted by a 
NaCl gradient (from 0 to 1000 mM) in the same buffer. 
Prior to crystallography, ion exchange purified proteins were further 
purified by gel filtration chromatography on a Superdex 75 column (GE 
Healthcare) in final buffer (200 mM NaCl, 20 mM tris.Cl pH=8.0, 2 mM DTT) and 
concentrated using centrifugal concentrators (Amicon). To form the SpaO-
OrgB::lysozyme complex for crystallization, cation exchange purified 
OrgB(1-30)::T4 lysozyme was mixed with an excess of anion exchange purified 
SpaO(145-213) + SpaO(232-297) and allowed to incubate overnight at 4°C. The 
SpaO-OrgB::lysozyme complex was then purified by gel filtration 
chromatography. To form the FliM::FliN-FliH::lysozyme complex for 
crystallization, anion exchange purified FliM(245-334)::FliN(5-137) was mixed 
with an excess of cation exchange purified FliH(1-18)::T4 lysozyme and allowed 
to incubate overnight at 4°C. The FliM::FliN-FliH::lysozyme complex was then 
purified by gel filtration chromatography.
Protein samples were analyzed by SDS-PAGE on 15% polyacrylamide 
gels. Samples were run in Laemmli running buffer (192 mM glycine, 25 mM tris, 
0.1% w/v SDS) unless a component of interest was less than 15 kDa, in which 
case tris-tricine running buffer was used instead (100 mM tris, 100 mM tricine, 
0.1% w/v SDS). Gels were stained with coomassie (2 mg/mL coomassie dye in 
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50% methanol, 40% water, 10% acetic acid) and destained in 30% methanol, 
60% water, 10% acetic acid).
7.4 Crystallization 
All proteins were crystallized by hanging drop vapor diffusion with 1:1 and 2:1 
ratios of protein (in final buffer) to precipitant at 25°C (except where noted). For 
crystallization, SpaO(232-297) and FliM(245-334)::FliN(5-137) were purified 
under native conditions; SpaO(145-213) and SpaO(232-297) were purified under 
denaturing conditions and co-refolded; the T4 lysozyme fusions were purified 
under denaturing conditions, refolded, and mixed with their cognate SPOA1-
SPOA2 as described above. The protein concentrations, crystallization buffers, 
and cryoprotection conditions for each protein or complex are as follows:
SpaO(232-297) was concentrated to 8 mg/mL and crystallized with 35% 
PEG400, 200 mM calcium acetate, 100 mM sodium acetate pH=5.0. Crystals 
were cryoprotected in the mother liquor. Microseeding was employed to enhance 
crystal uniformity and diffraction.  Briefly, crystals to be seeded were harvested in 
precipitant solution and vortexed in a microfuge tube with a small stir bar for ~60 
s.  The slurry of microseeds was serially dilluted (5-10-fold steps) in precipitant 
solution and 5 selected microseed-precipitant mixtures were mixed with fresh 
protein as in a normal hanging drop experiment.
SpaO(145-213) + SpaO(232-297) was concentrated to 12 mg/mL and 
crystallized with 25% PEG400, 10% isopropanol, 100 mM sodium citrate pH=5.6 
at 4°C. Microseeding (as above) was employed to enhance crystal uniformity and 
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diffraction. Crystals were cryoprotected in mother liquor with the PEG400 
concentration raised to 37.5%.
SpaO(145-213) + SpaO(232-297) + OrgB(1-30)::T4 lysozyme was 
concentrated to 18.5 mg/mL and crystallized with 25% PEG3350, 200 mM 
ammonium formate, 100 mM sodium acetate pH=5.0. Microseeding (as above) 
was employed to enhance crystal uniformity and diffraction. Crystals were 
cryoprotected in 30% PEG3350, 10% glycerol, 200 mM ammonium acetate, 100 
mM sodium acetate pH=5.0.
SpaO(145-213, SeMet) + SpaO(232-297, SeMet) + OrgB(1-30)::T4 
lysozyme (native) was concentrated to 18 mg/mL, supplemented with 50 mM 
maltose, and crystallized with 25% PEG3350, 200 mM ammonium formate, 100 
mM sodium acetate pH=5.0. Microseeding (as above) was employed to enhance 
crystal uniformity and diffraction. Crystals were cryoprotected in 25% PEG3350, 
10% ethylene glycol, 200 mM ammonium formate, 100 mM sodium acetate 
pH=5.0, 50 mM maltose.
FliM(245-334)::FliN(5-137) was concentrated to 7.5 mg/mL and 
crystallized with 2.2 M NaCl, 100 mM imidazole.Cl pH=8.0. Crystals were 
cryoprotected with 2 M NaCl, 100 mM imidazole.Cl pH=8.0, 30% glycerol.
FliM(245-334)::FliN(5-137) + FliH(1-18)::T4 lysozyme was concentrated to 
17 mg/mL and crystallized with 11% PEG400, 100 mM sodium potassium 
phosphate pH=6.5. Crystals were cryoprotected with 40% PEG400, 200 mM 
sodium potassium phosphate pH=6.5.
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7.5 Structure determination 
Data were collected at the National Synchrotron Light Source (Brookhaven 
National Laboratory) beamline X29A at a temperature of -173°C using the 
following X-ray wavelengths: 0.979 Å for SeMet crystals, 1.075 Å for native 
crystals. Diffraction data sets were indexed and integrated in iMOSFLM (198) 
and scaled and reduced with AIMLESS (199). Data sets were truncated at I/
σI>2.0, and all sets were determined to have a CC1/2>0.7 in the outermost 
resolution shell (200). 
The PHENIX program suite (201) was used to solve the crystallographic 
phase problem. SpaO(232-297), SpaO(145-213) + SpaO(232-297), and 
FliM(245-334)::FliN(5-137) were solved by SeMet single wavelength anomalous 
diffraction in Autosol. The SPOA1-SPOA2-APAR::lysozyme structures were 
solved by molecular replacement in Phaser-MR using the experimentally phased 
cognate SPOA1-SPOA2 structure and T4 lysozyme (PDB 2LZM). Structures 
were built in Phenix (Autobuild) with additional manual model building performed 
in Coot (202). Structures were refined and validated in Phenix. SpaO(145-213) + 
SpaO(232-297) + OrgB(1-30)::T4 lysozyme crystals exhibited twinning and were 
refined in Phenix using the twin law l,-k,h. ANODE (186) was used to perform 
post-hoc analysis of anomalous scatters in SpaO(145-213, SeMet) + SpaO 
(232-297, SeMet) + OrgB(1-30)::T4 lysozyme crystals, providing additional 
empirical support for the SpaO-OrgB model coordinates. Except where indicated, 
all representations of models and maps for figures were produced in QtMG (203). 
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7.6 NMR spectroscopy 
The NMR sample of refolded SpaO(140-297) consisted of 0.3 mM U-2H/15N/13C 
labeled protein in 10 mM citrate buffer at pH 5.6 with 90%H2O/10%D2O (v/v), 
100 mM NaCl, and 1 mM dithiothreitol. For comparison of the apo and APAR-
bound forms, 15N/13C-labeled SpaO(140-297) was co-refolded with an excess of 
unlabeled thioredoxin::OrgB(2-30). The thioredoxin solublization tag was cleaved 
off by overnight incubation with HRV 3C protease. Protease and affinity tags 
were removed on NiNTA resin and the SpaO-OrgB complex was separated from 
the majority of free thioredoxin by Superdex75 gel filtration chromatography. The 
final concentration of the protein complex was 0.2 mM in 10 mM citrate buffer at 
pH 5.6 supplemented with 10% v/v deuterium oxide, 100 mM NaCl, and 2 mM 
dithiothreitol.
The NMR data were collected on Bruker 600, 800, and 900 MHz AVANCE 
spectrometers equipped with TCI/TXI CryoProbes™ at 20°C for the apo-SpaO 
and 30°C for the APAR-bound forms. For resonance assignments of apo-SpaO, 
transverse relaxation optimized (TROSY) triple resonance (204) experiments 
including trHNCO, trHN(CA)CO, trHNCA, trHN(CO)CA, trHNCACB and 
trHN(CO)CACB were acquired at 600 and 900 MHz. A 15N-NOESY-HSQC 
spectrum with 100 ms mixing time was also acquired at 900 MHz. To assign 
APAR-bound SpaO, a suite of conventional backbone experiments (205) were 
acquired at 600 and 800 MHz.
The data were processed in Topspin 2.1 spectra and analyzed using the 
Autolink module in CARA 1.5 (206). The heteronuclear chemical shifts were 
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analyzed using the TALOS+ (181) database to predict the secondary structure of 
the protein. The weighted CSD were calculated from amide proton (δH) and 
nitrogen chemical shifts (δ15N) using the following equation: 
   
7.7 Co-affinity purification assays
For co-affinity purification of the SpaO-OrgB-InvC complex (Figures 3.1, 3.2, and 
3.3), the proteins indicated were co-expressed and purified under native 
conditions as described above.  
For the SPOA-APAR::lysozyme pulldown experiment (Figure 4.2), the 
indicated SPOA-containing proteins were Ni-affinity purified under native 
conditions, their affinity tags removed by overnight incubation with HRV protease 
3C, and they were further purified by anion exchange chromatography (as 
above). APAR::lysozyme fusions were separately purified under denaturing 
conditions and were subjected to cation exchange chromatography after 
refolding (as above). 1 mg of hexahistidine-tagged APAR::lysozyme fusion 
protein was mixed with 2 mg of the indicated SPOA-containing protein in 0.2 M 
NaCl, 20 mM tris.Cl pH=8.0 (final volume 4 mL) and incubated on ice for 2 h. The 
mixture was twice passed over 2 mL of NiNTA resin, washed with 8 mL wash 
buffer (200 mM NaCl, 20 mM tris.Cl pH=8.0, 5% v/v glycerol, 30 mM imidazole.Cl 
pH=8.0) and then eluted in 3.5 mL elution buffer (200 mM NaCl, 20 mM tris.Cl 






procedure was followed but glycerol was excluded from the wash and elution 
buffers, and 2 x 5 mL washes were used instead of 1 x 8 mL, which reduced 
background binding.
For the InvA-APAR binding experiment (Figure 3.14), all proteins were 
purified under native conditions, the OrgB(1-30)::Cerulean fusion was cleaved 
from its affinity tag with 3C protease, and the proteins were further purified by 
anion exchange chromatography (as above). 125 µM OrgB(1-30)::Cerulean was 
mixed with 125 µM double hexahistidine-tagged InvA(316-686) or 
SpaO(140-297) in a final volume of 1 mL (0.2 M NaCl, 20 mM tris.Cl pH=8.0, 5 
mM β-mercaptoethanol). After 4 h on ice, mixtures were passed over 1 mL NiNTA 
resin, washed with 6 mL of wash buffer (200 mM NaCl, 20 mM tris.Cl pH=8.0, 5% 
v/v glycerol, 30 mM imidazole.Cl pH=8.0) and then eluted in 4 mL of elution 
buffer (200 mM NaCl, 20 mM tris.Cl pH=8.0, 5% v/v glycerol, 360 mM 
imidazole.Cl pH=8.0).
For the SPOA2-NTD binding experiment (Figure 5.1), double 
hexahistidine-tagged SpaO(232-297) was purified under native conditions and 
anion exchange purified without removal of the affinity tags. SpaO(1-142)::T4 
lysozyme was purified under denaturing conditions, refolded, affinity tags 
removed with 3C protease, and further purified by cation exchange 
chromatography. 1 mg of double hexahistidine-tagged SpaO(232-297) was 
mixed with 2 mg of SpaO(1-142)::T4 lysozyme in a total volume of 4 mL buffer 
(0.2 M NaCl, 20 mM tris.Cl pH 7.0). After 2 h on ice, mixtures were passed over 
1.5 mL NiNTA resin, washed with 8 mL of wash buffer (200 mM NaCl, 20 mM 
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tris.Cl pH=7.0, 30 mM imidazole.Cl pH=7.0), washed again with 5 mL wash buffer 
and then eluted in 4 mL of elution buffer (200 mM NaCl, 20 mM tris.Cl pH=7.0, 
360 mM imidazole.Cl pH=7.0).
7.8 Isothermal titration calorimetry
Natively purified, 3C-cleaved SpaO(140-297), SpaO(232-297), or 
OrgB(1-30)::Cerulean were anion exchange purified as described above. 
SpaO(1-142)::T4 lysozyme was purified under denaturing conditions, refolded, 
cleaved with 3C protease, and cation exchange purified as described above for 
APAR::T4 lysozyme fusions. For the experiments in Figure 3.12, proteins were 
dialyzed overnight against 0.2 M NaCl, 20 mM tris.Cl pH=8.0, 5 mM β-
mercaptoethanol. SpaO constructs were concentrated to 1 mM and injected into 
100 µM OrgB(1-30)::Cerulean (or buffer for background subtraction). For the 
experiments in Figure 5.2, proteins were dialyzed overnight against 150 mM 
NaCl, 10 mM HEPES.Na pH=7.0, 5 mM β-mercaptoethanol. SpaO(232-297) 
concentrated to 1 mM (dimer concentration) was injected into 100 µM 
SpaO(1-142)::T4 lysozyme or SpaO(140-297) (or buffer for background 
subtraction). All experiments were performed using an auto-ITC200 (GE 
Healthcare) and data were processed in Origin. Values reported in the text are 
the mean of 3 technical replicates ± standard deviation.
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7.9 In vitro secretion assay 
S. typhimurium of the indicated genotype were grown for 6 h at 37°C in LB 
medium with NaCl supplemented to a final concentration of 0.3 M.  Cells were 
pelleted by centrifugation at 3400 g for 0.5-1 h and the supernatants were 0.22 
µm filtered. Secreted proteins were precipitated from the filtered supernatants 
with 15% trichloroacetic acid overnight at 4°C. The precipitate was pelleted by 
centrifugation at 3400 g for 1 h at 4°C, resuspended in ice cold acetone and 
transferred to a microfuge tube. After 0.25 h on ice, the precipitate was harvested 
by centrifugation at 16,000 g for 0.75 h at 4°C and resuspended in 0.2 M tris.Cl 
pH=8.0, 0.2 M NaCl to neutralize any residual acid before the addition of SDS-
PAGE loading buffer. For plasmid complementation analysis, S. typhimurium 
were electroporated with SpaO sequences cloned into the pBAD vector and 
expression was induced with 0.01% arabinose for the entire duration of the 
experiment.
7.10 Fluorescence microscopy 
S. typhimurium were grown as for the in vitro secretion assay. Cells were 
harvested by centrifugation, washed 3 times in PBS, and fixed overnight with 4% 
formaldehyde in PBS at 4°C. Cells were again washed 3 times in PBS, 
counterstained with DAPI (Sigma Aldrich) and/or 10 mM Nile Red (Sigma-
Aldrich), and immobilized on poly-L-lysine (P4707, Sigma Aldrich) coated 
coverslips.  [Poly-L-lysine coating: Coverslips were incubated with 400 µL of 
0.01% poly-L-lysine for 1-2 h at room temperature, washed by immersion in 
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distilled water (rapidly, five times) and air dried.] Covers were mounted in Prolong 
Diamond (Life Technologies) and sealed with nail polish. Slides were imaged on 
a DeltaVision Image Restoration Microscope with a 100x objective (Applied 
Precision). Images were deconvoluted in Softworx (Applied Precision) and 
processed identically in ImageJ (NIH) and Photoshop (Adobe).
7.11 Western blotting
After SDS-PAGE, samples were transferred to nitrocellulose membranes 
(Amersham Hybond ECL) by electrophoresis overnight with a constant 60 mA 
current in tris-glycine transfer buffer (20 mM tris, 150 mM glycine in 20% 
methanol, 80% water). Blots were blocked at room temperature for 1h in TBST 
(20 mM tris.Cl pH=7.4, 400 mM NaCl, 0.2% v/v Tween-20) supplemented with 
5% w/v nonfat milk powder. Blots were incubated with primary antibody (mouse 
anti-FLAG M2, Sigma F1804, 1:2000) in TBST/5% milk for 4 h at room 
temperature, washed with TBST four times, and then incubated with secondary 
antibody (goat anti-mouse IgG conjugated to horseradish peroxidase, Sigma 
A4416, 1:2000) in TBST/5% milk for 2 h at room temperature. Blots were again 
washed four times in TBST and then developed using the ECL 2 Western Blotting 
Substrate kit (Pierce) as per manufacturers guidelines. Chemiluminescence was 
visualized on a LAS-3000 Intelligent Dark Box (Fuji).
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7.12 FRET
Fluorescence readings were performed on a Spectramax Gemini XS plate reader 
(Molecular Devices). Samples were excited with 435 nm light and emission 
measurements made at 540 nm (acceptor fluorescence) and 480 nm (donor 
fluorescence). Relative FRET efficiency was calculated as:
 
where IA is the fluorescence intensity of the Venus acceptor stimulated by the 
Cerulean donor (ex: 435 nm, em: 540 nm), and ID is the fluorescence intensity of 
the Cerulean donor stimulated at its own maximum excitation wavelength (ex: 
435 nm, em: 480 nm). FRET efficiency was scaled so that the background FRET 
of an equimolar mixture of Cerulean and Venus (“C+V”) was set to 0:
 
A positive FRET control comprised of Cerulean fused to Venus with a 5 amino 
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